

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 7 : <b>C12N 15/29, 15/55, 1/19, 1/21, 5/10, A01H 5/00, 5/10, C12N 9/22</b></p>		<p>A1</p>	<p>(11) International Publication Number: <b>WO 00/36109</b></p> <p>(43) International Publication Date: <b>22 June 2000 (22.06.00)</b></p>
<p>(21) International Application Number: <b>PCT/US99/27147</b></p> <p>(22) International Filing Date: <b>16 November 1999 (16.11.99)</b></p> <p>(30) Priority Data: <b>60/112,332 15 December 1998 (15.12.98) US</b></p> <p>(71) Applicant (for all designated States except US): <b>PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 800 Capital Square, 400 Locust Street, Des Moines, IA 50309 (US).</b></p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): <b>MAHAJAN, Pramod, B. [US/US]; 8029 Brookview Drive, Urbandale, IA 50322 (US).</b></p> <p>(74) Agents: <b>YATES, Michael, E. et al.; Darwin Building, 7100 N.W. 62nd Avenue, Johnston, IA 50131-1000 (US).</b></p>		<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: <b>MAIZE RAD2/FEN-1 ORTHOLOGUES AND USES THEREOF</b></p> <p>(57) Abstract</p> <p>The invention provides isolated maize Rad2/FEN-1 nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering maize Rad2/FEN-1 concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

- 1 -

## Maize Rad2/FEN-1 Orthologues and Uses Thereof

### TECHNICAL FIELD

The present invention relates generally to plant molecular biology. More 5 specifically, it relates to nucleic acids and methods for modulating their expression in plants.

### BACKGROUND OF THE INVENTION

Transgenic plant product development by conventional transformation and 10 breeding efforts is a slow and unpredictable process. Gene targeting systems can overcome such problems as expression variability, unpredictable impacts of random gene insertion on agronomic performance, and the large number of experiments that need to be conducted to obtain ideal transgenic plants. Such systems can also provide approaches to manipulating endogenous genes.

15 Gene targeting systems require the ability to focus the recombination process to favor the recovery of desired targeting events. The natural cellular DNA repair and recombination machinery consists of a complex array of protein components interacting in a highly controlled manner to ensure that the fidelity of the genome is conserved throughout the many internal events or external stimuli experienced during each cell 20 cycle. The ability to manipulate this machinery requires an understanding of how specific proteins are involved in the process, and how the genes that encode those proteins are regulated. Because many different protein components may be involved in gene targeting, the availability of host-specific genes and proteins could avoid possible problems of incompatibility associated with molecular interactions due to heterologous 25 components.

The RAD2 gene of the budding yeast *Saccharomyces cerevisiae* is one of several genes known to be important in excision repair (1). It encodes an endonuclease that specifically cleaves single-stranded DNA in the 5' to 3' orientation. The yeast RAD2 gene and encoded protein (Rad2) exhibit high homology to a human DNA repair protein 30 XP-G (2) and the structure specific Flap Endonuclease-1 or FEN-1 (3, 4). Human FEN-1 is a 380 amino acid protein which cleaves DNA flap strands that terminate with 5' single strand ends. This cleavage is flap strand specific and independent of the flap strand sequence or length (3). Other branched structures such as Holliday junctions or

double D loop are not cleaved by FEN-1 (3). Members of this family have also been cloned from the budding yeast (5), *Xenopus* (6), and mouse (7), as well as the archaeabacteria (8). Recently, Kimura et al. have also characterized a structure-specific endonuclease from *Brassica oleracea* (9).

5        Genetic and biochemical studies have established that the Rad2/FEN-1 protein is  
a structure specific endonuclease (8, 10). Moreover, under certain reaction conditions, it  
also acts as an exonuclease (8, 10). The endonucleolytic activity is essential in DNA  
replication as well as the nucleotide excision repair reactions (8, 10). The exonucleolytic  
activity is involved in double strand break repair and end joining (8, 10). The protein is  
10      also useful in strand exchange reactions during homologous recombination (8, 10).  
These functions could prove to be very useful in gene targeting and in the production of  
male sterile plants. For example, the efficiency of gene targeting can be improved by  
the overexpression of exogenous Rad2/FEN-1 while male sterile plants can be produced  
by the down-regulation of Rad2/FEN-1 expression.

15 The regulation of DNA repair and recombination in plant systems by the modulation of maize Rad2/FEN-1 will provide improved and expanded methods of gene targeting. The need in the art for methods to regulate gene targeting and to modulate male sterility is clear. The present invention provides these and other advantages.

## 20 SUMMARY OF THE INVENTION

Generally, it is the object of the present invention to provide nucleic acids and proteins relating to maize Rad2/FEN-1. It is an object of the present invention to provide: 1) antigenic fragments of the proteins of the present invention; 2) transgenic plants comprising the nucleic acids of the present invention; 3) methods for modulating, in a transgenic plant, the expression of the nucleic acids of the present invention.

Therefore, in one aspect, the present invention relates to an isolated nucleic acid comprising a member selected from the group consisting of (a) a polynucleotide having a specified sequence identity to a polynucleotide encoding a polypeptide of the present invention; (b) a polynucleotide which is complementary to the polynucleotide of (a); and, 30 (c) a polynucleotide comprising a specified number of contiguous nucleotides from a polynucleotide of (a) or (b). The isolated nucleic acid can be DNA.

- 3 -

In another aspect, the present invention relates to recombinant expression cassettes, comprising a nucleic acid of the present invention operably linked to a promoter.

5 In another aspect, the present invention is directed to a host cell into which has been introduced the recombinant expression cassette.

In a further aspect, the present invention relates to an isolated protein comprising a polypeptide having a specified number of contiguous amino acids encoded by an isolated nucleic acid of the present invention.

10 In another aspect, the present invention relates to an isolated nucleic acid comprising a polynucleotide of specified length which selectively hybridizes under stringent conditions to a polynucleotide of the present invention, or a complement thereof. In some embodiments, the isolated nucleic acid is operably linked to a promoter.

15 In another aspect, the present invention relates to a recombinant expression cassette comprising a nucleic acid amplified from a library as referred to *supra*, wherein the nucleic acid is operably linked to a promoter. In some embodiments, the present invention relates to a host cell transfected with this recombinant expression cassette. In some embodiments, the present invention relates to a protein of the present invention which is produced from this host cell.

20 In yet another aspect, the present invention relates to a transgenic plant comprising a recombinant expression cassette comprising a plant promoter operably linked to any of the isolated nucleic acids of the present invention. The present invention also provides transgenic seed from the transgenic plant.

25 **Definitions**

Units, prefixes, and symbols may be denoted in their SI accepted form. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

30 Numeric ranges are inclusive of the numbers defining the range and include each integer within the defined range. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be

referred to by their commonly accepted single-letter codes. The terms defined below are more fully defined by reference to the specification as a whole.

By "amplified" is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least 5 one of the nucleic acid sequences as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., *Diagnostic Molecular Microbiology: 10 Principles and Applications*, D. H. Persing *et al.*, Ed., American Society for Microbiology, Washington, D.C. (1993). The product of amplification is termed an amplicon.

The term "antibody" includes reference to antigen binding forms of antibodies (e.g., Fab, F(ab)<sub>2</sub>). The term "antibody" frequently refers to a polypeptide substantially 15 encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). However, while various antibody fragments can be defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, 20 also includes antibody fragments such as single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions from different species), humanized antibodies (i.e., comprising a complementarity determining region (CDR) from a non-human source) and heteroconjugate antibodies (e.g., bispecific antibodies).

The term "antigen" includes reference to a substance to which an antibody can be 25 generated and/or to which the antibody is specifically immunoreactive. The specific immunoreactive sites within the antigen are known as epitopes or antigenic determinants. These epitopes can be a linear array of monomers in a polymeric composition - such as amino acids in a protein - or consist of or comprise a more complex secondary or tertiary structure. Those of skill will recognize that all immunogens (i.e., substances capable of 30 eliciting an immune response) are antigens; however some antigens, such as haptens, are not immunogens but may be made immunogenic by coupling to a carrier molecule. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage

- 5 -

or similar vectors. See, e.g., Huse *et al.*, *Science* 246: 1275-1281 (1989); and Ward, *et al.*, *Nature* 341: 544-546 (1989); and Vaughan *et al.*, *Nature Biotech.* 14: 309-314 (1996).

As used herein, "antisense orientation" includes reference to a duplex 5 polynucleotide sequence which is operably linked to a promoter in an orientation where the antisense strand is transcribed. The antisense strand is sufficiently complementary to an endogenous transcription product such that translation of the endogenous transcription product is often inhibited.

As used herein, "chromosomal region" includes reference to a length of a 10 chromosome which may be measured by reference to the linear segment of DNA which it comprises. The chromosomal region can be defined by reference to two unique DNA sequences, i.e., markers.

The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively 15 modified variants refers to those nucleic acids which encode identical or conservatively modified variants of the amino acid sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be 20 altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations" and represent one species of conservatively modified variation. Every nucleic acid sequence herein which encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation of the nucleic acid. One of ordinary skill will recognize that each codon 25 in a nucleic acid (except AUG, which is ordinarily the only codon for methionine; and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide of the present invention is implicit in each described polypeptide sequence and is within the scope of the present invention.

As to amino acid sequences, one of skill will recognize that individual 30 substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the

alteration results in the substitution of an amino acid with a chemically similar amino acid. Thus, any number of amino acid residues selected from the group of integers consisting of from 1 to 15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 10 alterations can be made. Conservatively modified variants typically provide similar 5 biological activity as the unmodified polypeptide sequence from which they are derived. For example, substrate specificity, enzyme activity, or ligand/receptor binding is generally at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the native protein for its native substrate. Conservative substitution tables providing functionally similar amino acids are well known in the art.

10 The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 15 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See also, Creighton (1984) Proteins W.H. Freeman and Company.

20 By "encoding" or "encoded", with respect to a specified nucleic acid, is meant comprising the information for translation into the specified protein. A nucleic acid encoding a protein may comprise non-translated sequences (e.g., introns) within translated regions of the nucleic acid, or may lack such intervening non-translated sequences (e.g., as in cDNA). The information by which a protein is encoded is specified by the use of codons. Typically, the amino acid sequence is encoded by the 25 nucleic acid using the "universal" genetic code. However, variants of the universal code, such as are present in some plant, animal, and fungal mitochondria, the bacterium *Mycoplasma capricolum*, or the ciliate *Macronucleus*, may be used when the nucleic acid is expressed therein.

When the nucleic acid is prepared or altered synthetically, advantage can be taken 30 of known codon preferences of the intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of

monocotyledons or dicotyledons as these preferences have been shown to differ (Murray *et al. Nucl. Acids Res.* 17: 477-498 (1989)). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray *et al.*, *supra*.

5 As used herein "full-length sequence" in reference to a specified polynucleotide or its encoded protein means having the entire amino acid sequence of, a native (non-synthetic), endogenous, biologically active form of the specified protein. Methods to determine whether a sequence is full-length are well known in the art including such exemplary techniques as northern or western blots, primer extension, S1 protection, and 10 ribonuclease protection. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997). Comparison to known full-length homologous (orthologous and/or paralogous) sequences can also be used to identify full-length sequences of the present invention. Additionally, consensus sequences typically present at the 5' and 3' untranslated regions of mRNA aid in the identification of a 15 polynucleotide as full-length. For example, the consensus sequence ANNNNAUGG, where the underlined codon represents the N-terminal methionine, aids in determining whether the polynucleotide has a complete 5' end. Consensus sequences at the 3' end, such as polyadenylation sequences, aid in determining whether the polynucleotide has a complete 3' end.

20 As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if 25 from the same species, one or both are substantially modified from their original form. A heterologous protein may originate from a foreign species or, if from the same species, is substantially modified from its original form by deliberate human intervention.

30 By "host cell" is meant a cell which contains a vector and supports the replication and/or expression of the vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells. A particularly preferred monocotyledonous host cell is a maize host cell.

The term "hybridization complex" includes reference to a duplex nucleic acid structure formed by two single-stranded nucleic acid sequences selectively hybridized with each other.

By "immunologically reactive conditions" or "immunoreactive conditions" is meant conditions which allow an antibody, reactive to a particular epitope, to bind to that epitope to a detectably greater degree (e.g., at least 2-fold over background) than the antibody binds to substantially any other epitopes in a reaction mixture comprising the particular epitope. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols. See Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions.

The term "introduced" in the context of inserting a nucleic acid into a cell, means "transfection" or "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

The terms "isolated" refers to material, such as a nucleic acid or a protein, which is: (1) substantially or essentially free from components that normally accompany or interact with it as found in its naturally occurring environment. The isolated material optionally comprises material not found with the material in its natural environment; or (2) if the material is in its natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a location in the cell (e.g., genome or subcellular organelle) not native to a material found in that environment. The alteration to yield the synthetic material can be performed on the material within or removed from its natural state. For example, a naturally occurring nucleic acid becomes an isolated nucleic acid if it is altered, or if it is transcribed from DNA which has been altered, by means of human intervention performed within the cell from which it originates. See, e.g., Compounds and Methods for Site Directed Mutagenesis in Eukaryotic Cells, Kmiec, U.S. Patent No. 5,565,350; *In Vivo* Homologous Sequence Targeting in Eukaryotic Cells; Zarling *et al.*, PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., a promoter) becomes isolated if it is

introduced by non-naturally occurring means to a locus of the genome not native to that nucleic acid. Nucleic acids which are "isolated" as defined herein, are also referred to as "heterologous" nucleic acids.

Unless otherwise stated, the term "maize Rad2/FEN-1 nucleic acid" is a nucleic acid of the present invention and means a nucleic acid comprising a polynucleotide of the present invention (a "maize Rad2/FEN-1 polynucleotide") encoding a maize Rad2/FEN-1 polypeptide. A "maize Rad2/FEN-1 gene" is a gene of the present invention and refers to a heterologous genomic form of a full-length maize Rad2/FEN-1 polynucleotide.

As used herein, "localized within the chromosomal region defined by and including" with respect to particular markers includes reference to a contiguous length of a chromosome delimited by and including the stated markers.

As used herein, "marker" includes reference to a locus on a chromosome that serves to identify a unique position on the chromosome. A "polymorphic marker" includes reference to a marker which appears in multiple forms (alleles) such that different forms of the marker, when they are present in a homologous pair, allow transmission of each of the chromosomes of that pair to be followed. A genotype may be defined by use of one or a plurality of markers.

As used herein, "nucleic acid" includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids).

By "nucleic acid library" is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, 2nd ed., Vol. 1-3 (1989); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994).

-10-

As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are 5 contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. Plant cell, as used herein includes, without limitation, seeds, suspension cultures, 10 embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. A particularly preferred plant is *Zea mays*.

As used herein, "polynucleotide" includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogs thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization 15 conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally occurring nucleotide(s). A polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof. Thus, DNAs or RNAs with backbones modified for stability or for other reasons 20 are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that 25 serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of 30 viruses and cells, including among other things, simple and complex cells.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in

which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to 5 antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids. The terms "polypeptide", "peptide" and "protein" are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. It will be appreciated, as is well known and as noted above, that polypeptides are not always 10 entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslational events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely 15 synthetic methods, as well. Further, this invention contemplates the use of both the methionine-containing and the methionine-less amino terminal variants of the protein of the invention.

As used herein "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase 20 and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells whether nor not its origin is a plant cell. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria which comprise genes expressed in plant cells such *Agrobacterium* or *Rhizobium*. Examples of promoters under developmental control include promoters 25 that preferentially initiate transcription in certain tissues, such as leaves, roots, or seeds. Such promoters are referred to as "tissue preferred". Promoters which initiate transcription only in certain tissue are referred to as "tissue specific". A "cell type" specific promoter primarily drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" or "repressible" promoter 30 is a promoter which is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue specific, tissue preferred, cell type specific, and inducible promoters constitute the class of "non-constitutive" promoters. A

"constitutive" promoter is a promoter which is active under most environmental conditions.

The term "maize Rad2/FEN-1 polypeptide" is a polypeptide of the present invention and refers to one or more amino acid sequences, in glycosylated or non-glycosylated form. The term is also inclusive of fragments, variants, homologs, alleles or precursors (e.g., preproproteins or proproteins) thereof. A "maize Rad2/FEN-1 protein" is a protein of the present invention and comprises a maize Rad2/FEN-1 polypeptide.

As used herein "recombinant" includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under-expressed or not expressed at all as a result of deliberate human intervention. The term "recombinant" as used herein does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation/transduction/transposition) such as those occurring without deliberate human intervention.

As used herein, a "recombinant expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed, and a promoter.

The term "residue" or "amino acid residue" or "amino acid" are used interchangeably herein to refer to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively "protein"). The amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass non-natural analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.

The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than

its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, preferably 90% sequence identity, and most preferably 100% sequence identity (i.e., complementary) with each other.

5        The term "specifically reactive", includes reference to a binding reaction between an antibody and a protein having an epitope recognized by the antigen binding site of the antibody. This binding reaction is determinative of the presence of a protein having the recognized epitope amongst the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified  
10      antibodies bind to an analyte having the recognized epitope to a substantially greater degree (e.g., at least 2-fold over background) than to substantially all other analytes lacking the epitope which are present in the sample.

15      Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the polypeptides of the present invention can be selected from to obtain antibodies specifically reactive with polypeptides of the present invention. The proteins used as immunogens can be in native conformation or denatured so as to provide a linear epitope.

20      A variety of immunoassay formats may be used to select antibodies specifically reactive with a particular protein (or other analyte). For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions that can be used to determine selective reactivity.

25      The terms "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which a probe will hybridize to its target sequence, to a detectably greater degree than other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing  
30      conditions, target sequences can be identified which are 100% complementary to the probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected

(heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, optionally less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 5 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS 10 (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include 15 hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the  $T_m$  can be approximated from the equation of Meinkoth and Wahl, *Anal. Biochem.*, 138:267-284 (1984):  $T_m = 81.5 \text{ } ^\circ\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 20 0.61 (\% \text{ form}) - 500/L$ ; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe.  $T_m$  is reduced 25 by about 1 °C for each 1% of mismatching; thus,  $T_m$ , hybridization and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with  $\geq 90\%$  identity are sought, the  $T_m$  can be decreased 10 °C. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point ( $T_m$ ) for the specific sequence and its complement at a defined ionic 30 strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4 °C lower than the thermal melting point ( $T_m$ ); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10 °C lower than the thermal melting point ( $T_m$ ); low stringency conditions can utilize a hybridization

and/or wash at 11, 12, 13, 14, 15, or 20 °C lower than the thermal melting point ( $T_m$ ). Using the equation, hybridization and wash compositions, and desired  $T_m$ , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in 5 a  $T_m$  of less than 45 °C (aqueous solution) or 32 °C (formamide solution) it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe 10 assays", Elsevier, New York (1993); and *Current Protocols in Molecular Biology*, Chapter 2, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

As used herein, "transgenic plant" includes reference to a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous 15 polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those 20 transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial 25 transformation, non-recombinant transposition, or spontaneous mutation.

As used herein, "vector" includes reference to a nucleic acid used in transfection of a host cell and into which can be inserted a polynucleotide. Vectors are often replicons. Expression vectors permit transcription of a nucleic acid inserted therein.

The following terms are used to describe the sequence relationships between two 30 or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.

5 (b) As used herein, "comparison window" means includes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence may be compared to a reference sequence and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, 10 the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of 15 matches.

Methods of alignment of sequences for comparison are well-known in the art.

Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.* 2: 482 (1981); by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970); by the 20 search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci.* 85: 2444 (1988); by computerized implementations of these algorithms, including, but not limited to: CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, 25 USA; the CLUSTAL program is well described by Higgins and Sharp, *Gene* 73: 237-244 (1988); Higgins and Sharp, *CABIOS* 5: 151-153 (1989); Corpet, *et al.*, *Nucleic Acids Research* 16: 10881-90 (1988); Huang, *et al.*, *Computer Applications in the Biosciences* 8: 155-65 (1992), and Pearson, *et al.*, *Methods in Molecular Biology* 24: 307-331 (1994). The BLAST family of programs which can be used for database 30 similarity searches includes: BLASTN for nucleotide query sequences against nucleotide database sequences; BLASTX for nucleotide query sequences against protein database sequences; BLASTP for protein query sequences against protein database sequences; TBLASTN for protein query sequences against nucleotide database sequences; and

TBLASTX for nucleotide query sequences against nucleotide database sequences. See, *Current Protocols in Molecular Biology*, Chapter 19, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

GAP uses the algorithm of Needleman and Wunsch (J. Mol. Biol. 48: 443-453, 5 1970) to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension 10 penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of the length of the gap times 15 the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap creation and gap extension penalties 20 can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can each independently be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater.

25 GAP presents one member of the family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols 30 that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff & Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

35 Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul *et al.*, *Nucleic Acids Res.* 25:3389-3402, 1997; Altschul *et al.*, *J. Mol. Bio.* 215: 403-410, 1990) or to the value obtained using the GAP program using default parameters

(see the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA).

Software for performing BLAST analyses is publicly available, e.g., through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This 5 algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find 10 longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the 15 cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. 20 The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff 25 (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also 30 performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5877 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.

BLAST searches assume that proteins can be modeled as random sequences. However, many real proteins comprise regions of nonrandom sequences which may be homopolymeric tracts, short-period repeats, or regions enriched in one or more amino

acids. Such low-complexity regions may be aligned between unrelated proteins even though other regions of the protein are entirely dissimilar. A number of low-complexity filter programs can be employed to reduce such low-complexity alignments. For example, the SEG (Wooten and Federhen, *Comput. Chem.*, 17:149-163 (1993)) and 5 XNU (Claverie and States, *Comput. Chem.*, 17:191-201 (1993)) low-complexity filters can be employed alone or in combination.

(c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned for maximum correspondence over a 10 specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. 15 Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences which differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a 20 full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Meyers and Miller, *Computer Applic. Biol. Sci.*, 4: 11-17 (1988) e.g., as 25 implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

(d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may 30 comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the

- 20 -

number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

(e) (i) The term "substantial identity" of polynucleotide sequences means 5 that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide 10 sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two 15 molecules hybridize to each other under stringent conditions. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences 20 are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e) (ii) The terms "substantial identity" in the context of a peptide indicates 25 that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window.

Optionally, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970). An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to 30 a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides which are "substantially similar" share sequences as noted above except that residue positions which are not identical may differ by conservative amino acid changes.

## DETAILED DESCRIPTION OF THE INVENTION

Overview

The present invention provides, among other things, compositions and methods for modulating (i.e., increasing or decreasing) the level of polypeptides of the present invention in plants. In particular, the polypeptides of the present invention can be expressed at developmental stages, in tissues, and/or in quantities which are uncharacteristic of non-recombinantly engineered plants. Thus, the present invention provides utility in such exemplary applications as modulating male sterility by downregulation of expression and modulating gene targeting by overexpression, particularly in maize.

The present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene of the present invention to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts. For example, isolated nucleic acids of the present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene (e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in screening assays of compounds, for detection of any number of allelic variants (polymorphisms) of the gene, or for use as molecular markers in plant breeding programs. The isolated nucleic acids of the present invention can also be used for recombinant expression of their encoded polypeptides, or for use as immunogens in the preparation and/or screening of antibodies. The isolated nucleic acids of the present invention can also be employed for use in sense or antisense suppression of one or more genes of the present invention in a host cell, tissue, or plant. Attachment of chemical agents which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids of the present invention can also be used to modulate transcription or translation.

The present invention also provides isolated proteins comprising a polypeptide of the present invention (e.g., preproenzyme, proenzyme, or enzymes). The present invention also provides proteins comprising at least one epitope from a polypeptide of the present invention. The proteins of the present invention can be employed in assays for enzyme agonists or antagonists of enzyme function, or for use as immunogens or antigens to obtain antibodies specifically immunoreactive with a protein of the present

-22-

invention. Such antibodies can be used in assays for expression levels, for identifying and/or isolating nucleic acids of the present invention from expression libraries, or for purification of polypeptides of the present invention.

The isolated nucleic acids and proteins of the present invention can be used over a broad range of plant types, particularly monocots such as the species of the family *Gramineae* including *Sorghum bicolor* and *Zea mays*. The isolated nucleic acid and proteins of the present invention can also be used in species from the genera: *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panieum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, *Avena*, *Hordeum*, *Secale*, and *Triticum*.

15

### Nucleic Acids

The present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide of the present invention.

20

A polynucleotide of the present invention is inclusive of:

(a) a polynucleotide encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8 and conservatively modified and polymorphic variants thereof, including exemplary polynucleotides of SEQ ID NOS: 1, 3, 5, 7; the polynucleotide sequences of the invention also include the maize Rad2/FEN-1 polynucleotide sequence of SEQ ID NO. 3 as contained in a plasmid deposited with American Type Culture Collection (ATCC) and assigned Accession Number PTA-533.

(b) a polynucleotide which is the product of amplification from a *Zea mays* nucleic acid library using primer pairs which selectively hybridize under stringent conditions to loci within a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, or the sequence of SEQ ID NO. 3 as contained in the ATCC deposit assigned Accession Number PTA-533 wherein the polynucleotide has substantial sequence identity to a polynucleotide selected from the group consisting of SEQ ID

25

30 NOS: 1, 3, 5, 7, or the sequence of SEQ ID NO. 3 as contained in the ATCC deposit assigned Accession Number PTA-533 wherein the polynucleotide has substantial sequence identity to a polynucleotide selected from the group consisting of SEQ ID

- 23 -

NOS: 1, 3, 5, 7; or the sequence of SEQ ID NO. 3 as contained in the ATCC deposit assigned Accession Number PTA-533.

- (c) a polynucleotide which selectively hybridizes to a polynucleotide of (a) or (b);
- (d) a polynucleotide having a specified sequence identity with polynucleotides of 5 (a), (b), or (c);
- (e) a polynucleotide encoding a protein having a specified number of contiguous amino acids from a prototype polypeptide, wherein the protein is specifically recognized by antisera elicited by presentation of the protein and wherein the protein does not detectably immunoreact to antisera which has been fully immunosorbed with the protein;
- 10 (f) complementary sequences of polynucleotides of (a), (b), (c), (d), or (e); and
- (g) a polynucleotide comprising at least a specific number of contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), (e), or (f).

The polynucleotide of SEQ ID NO: 3 is contained in a plasmid deposited with American Type Culture Collection (ATCC) on August 17, 1999 and assigned Accession 15 Number PTA-533. American Type Culture Collection is located at 10801 University Blvd., Manassas, VA 20110-2209.

The ATCC deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The deposit is provided as a convenience to those of skill in the art and is not 20 an admission that a deposit is required under 35 U.S.C. Section 112. The deposited sequences, as well as the polypeptides encoded by the sequences, are incorporated herein by reference and control in the event of any conflict, such as a sequencing error, with the description in this application.

25 *A. Polynucleotides Encoding A Polypeptide of the Present Invention or Conservatively Modified or Polymorphic Variants Thereof*

As indicated in (a), *supra*, the present invention provides isolated nucleic acids comprising a polynucleotide of the present invention, wherein the polynucleotide encodes a polypeptide of the present invention, or conservatively modified or polymorphic 30 variants thereof. Those of skill in the art will recognize that the degeneracy of the genetic code allows for a plurality of polynucleotides to encode for the identical amino acid sequence. Such "silent variations" can be used, for example, to selectively hybridize and detect allelic variants of polynucleotides of the present invention.

-24-

Accordingly, the present invention includes polynucleotides of SEQ ID NOS: 1, 3, 5, 7, and the sequence as contained in the ATCC deposit assigned Accession Number PTA-533, and silent variations of polynucleotides encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8. The present invention further provides isolated nucleic acids comprising 5 polynucleotides encoding conservatively modified variants of a polypeptide of SEQ ID NOS: 2, 4, 6, 8. Conservatively modified variants can be used to generate or select antibodies immunoreactive to the non-variant polypeptide. Additionally, the present invention further provides isolated nucleic acids comprising polynucleotides encoding one or more polymorphic (allelic) variants of polypeptides/polynucleotides.

10 Polymorphic variants are frequently used to follow segregation of chromosomal regions in, for example, marker assisted selection methods for crop improvement.

*B. Polynucleotides Amplified from a Zea mays Nucleic Acid Library*

As indicated in (b), *supra*, the present invention provides an isolated nucleic acid 15 comprising a polynucleotide of the present invention, wherein the polynucleotides are amplified from a *Zea mays* nucleic acid library. *Zea mays* lines B73, PHRE1, A632, BMS-P2#10, W23, and Mo17 are known and publicly available. Other publicly known and available maize lines can be obtained from the Maize Genetics Cooperation (Urbana, IL). The nucleic acid library may be a cDNA library, a genomic library, or a library 20 generally constructed from nuclear transcripts at any stage of intron processing. cDNA libraries can be normalized to increase the representation of relatively rare cDNAs. In optional embodiments, the cDNA library is constructed using a full-length cDNA synthesis method. Examples of such methods include Oligo-Capping (Maruyama, K. and Sugano, S. *Gene* 138: 171-174, 1994), Biotinylated CAP Trapper (Carninci, P., 25 Kvan, C., *et al. Genomics* 37: 327-336, 1996), and CAP Retention Procedure (Edery, E., Chu, L.L., *et al. Molecular and Cellular Biology* 15: 3363-3371, 1995). cDNA synthesis is often catalyzed at 50-55°C to prevent formation of RNA secondary 30 structure. Examples of reverse transcriptases that are relatively stable at these temperatures are SuperScript II Reverse Transcriptase (Life Technologies, Inc.), AMV Reverse Transcriptase (Boehringer Mannheim) and RetroAmp Reverse Transcriptase (Epicentre). Rapidly growing tissues, or rapidly dividing cells are preferably used as mRNA sources.

- 25 -

The present invention also provides subsequences of the polynucleotides of the present invention. A variety of subsequences can be obtained using primers which selectively hybridize under stringent conditions to at least two sites within a polynucleotide of the present invention, or to two sites within the nucleic acid which 5 flank and comprise a polynucleotide of the present invention, or to a site within a polynucleotide of the present invention and a site within the nucleic acid which comprises it. Primers are chosen to selectively hybridize, under stringent hybridization conditions, to a polynucleotide of the present invention. Generally, the primers are complementary to a subsequence of the target nucleic acid which they amplify. As those 10 skilled in the art will appreciate, the sites to which the primer pairs will selectively hybridize are chosen such that a single contiguous nucleic acid can be formed under the desired amplification conditions.

In optional embodiments, the primers will be constructed so that they selectively hybridize under stringent conditions to a sequence (or its complement) within the target 15 nucleic acid which comprises the codon encoding the carboxy or amino terminal amino acid residue (i.e., the 3' terminal coding region and 5' terminal coding region, respectively) of the polynucleotides of the present invention. Optionally within these embodiments, the primers will be constructed to selectively hybridize entirely within the coding region of the target polynucleotide of the present invention such that the product 20 of amplification of a cDNA target will consist of the coding region of that cDNA. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length. Those of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e., annealing) to a target sequence. A 25 non-annealing sequence at the 5'end of a primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends of the amplicon.

The amplification products can be translated using expression systems well known to those of skill in the art and as discussed, *infra*. The resulting translation products can be confirmed as polypeptides of the present invention by, for example, 30 assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or verifying the presence of one or more linear epitopes which are specific to a polypeptide of the present invention. Methods for protein synthesis from PCR

- 26 -

derived templates are known in the art and available commercially. See, e.g., Amersham Life Sciences, Inc, Catalog '97, p.354.

Methods for obtaining 5' and/or 3' ends of a vector insert are well known in the art. See, e.g., RACE (Rapid Amplification of Complementary Ends) as described in

5 Frohman, M. A., in PCR Protocols: A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, Eds. (Academic Press, Inc., San Diego, 1990), pp. 28-38.); see also, U.S. Pat. No. 5,470,722, and *Current Protocols in Molecular Biology*, Unit 15.6, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); Frohman and Martin, *Techniques* 1:165 (1989).

10

### *C. Polynucleotides Which Selectively Hybridize to a Polynucleotide of (A) or (B)*

As indicated in (c), *supra*, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides selectively hybridize, under selective hybridization conditions, to a polynucleotide of paragraphs (A) or (B) as discussed, *supra*. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising the

~~polynucleotides of (A) or (B). For example, polynucleotides of the present invention can~~

be used to identify, isolate, or amplify partial or full-length clones in a deposited library.

In some embodiments, the polynucleotides are genomic or cDNA sequences isolated or otherwise complementary to a cDNA from a dicot or monocot nucleic acid library.

Exemplary species of monocots and dicots include, but are not limited to: corn, canola, soybean, cotton, wheat, sorghum, sunflower, oats, sugar cane, millet, barley, and rice.

Preferably, the cDNA library comprises at least 80% full-length sequences, preferably at least 85% or 90% full-length sequences, and more preferably at least 95% full-length

25 sequences. The cDNA libraries can be normalized to increase the representation of rare sequences. Low stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary

sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. Low stringency conditions allow selective hybridization of

30 sequences having about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

**D. Polynucleotides Having a Specific Sequence Identity with the Polynucleotides of (A), (B) or (C)**

As indicated in (d), *supra*, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides have a 5 specified identity at the nucleotide level to a polynucleotide as disclosed above in paragraphs (A), (B), or (C). The percentage of identity to a reference sequence is at least 60% and, rounded upwards to the nearest integer, can be expressed as an integer selected from the group of integers consisting of from 60 to 99. Thus, for example, the 10 percentage of identity to a reference sequence can be at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

15 Optionally, the polynucleotides of this embodiment will share an epitope with a polypeptide encoded by the polynucleotides of (A), (B), or (C). Thus, these polynucleotides encode a first polypeptide which elicits production of antisera comprising antibodies which are specifically reactive to a second polypeptide encoded by a polynucleotide of (A), (B), or (C). However, the first polypeptide does not bind to 20 antisera raised against itself when the antisera has been fully immunosorbed with the first polypeptide. Hence, the polynucleotides of this embodiment can be used to generate antibodies for use in, for example, the screening of expression libraries for nucleic acids comprising polynucleotides of (A), (B), or (C), or for purification of, or in immunoassays for, polypeptides encoded by the polynucleotides of (A), (B), or (C). The 25 polynucleotides of this embodiment embrace nucleic acid sequences which can be employed for selective hybridization to a polynucleotide encoding a polypeptide of the present invention.

25 Screening polypeptides for specific binding to antisera can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 30 5-100 amino acids long, and often from about 8 to 15 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains

the nucleotide sequence encoding the particular displayed peptide sequence. Such methods are described in PCT patent publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278. Other systems for generating libraries of peptides have aspects of both *in vitro* chemical synthesis and recombinant methods. See, PCT Patent publication Nos.

5 92/05258, 92/14843, and 96/19256. See also, U.S. Patent Nos. 5,658,754; and 5,643,768. Peptide display libraries, vectors, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, CA).

*E. Polynucleotides Encoding a Protein Having a Subsequence from a Prototype*

10 *Polypeptide and is Cross-Reactive to the Prototype Polypeptide*

As indicated in (e), *supra*, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides encode a protein having a subsequence of contiguous amino acids from a prototype polypeptide of the present invention such as are provided in (a), *supra*. The length of contiguous

15 amino acids from the prototype polypeptide is selected from the group of integers consisting of from at least 10 to the number of amino acids within the prototype sequence. Thus, for example, the polynucleotide can encode a polypeptide having a subsequence having at least 10, 15, 20, 25, 30, 35, 40, 45, or 50, contiguous amino acids from the prototype polypeptide. Further, the number of such subsequences 20 encoded by a polynucleotide of the instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

25 The proteins encoded by polynucleotides of this embodiment, when presented as an immunogen, elicit the production of polyclonal antibodies which specifically bind to a prototype polypeptide such as but not limited to, a polypeptide encoded by the polynucleotide of (a) or (b), *supra*. Generally, however, a protein encoded by a polynucleotide of this embodiment does not bind to antisera raised against the prototype polypeptide when the antisera has been fully immunosorbed with the prototype 30 polypeptide. Methods of making and assaying for antibody binding specificity/affinity are well known in the art. Exemplary immunoassay formats include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like.

In a preferred assay method, fully immunosorbed and pooled antisera which is elicited to the prototype polypeptide can be used in a competitive binding assay to test the protein. The concentration of the prototype polypeptide required to inhibit 50% of the binding of the antisera to the prototype polypeptide is determined. If the amount of the protein required to inhibit binding is less than twice the amount of the prototype protein, then the protein is said to specifically bind to the antisera elicited to the immunogen. Accordingly, the proteins of the present invention embrace allelic variants, conservatively modified variants, and minor recombinant modifications to a prototype polypeptide.

A polynucleotide of the present invention optionally encodes a protein having a molecular weight as the non-glycosylated protein within 20% of the molecular weight of the full-length non-glycosylated polypeptides of the present invention. Molecular weight can be readily determined by SDS-PAGE under reducing conditions. Preferably, the molecular weight is within 15% of a full length polypeptide of the present invention, more preferably within 10% or 5%, and most preferably within 3%, 2%, or 1% of a full length polypeptide of the present invention.

Optionally, the polynucleotides of this embodiment will encode a protein having a specific activity at least 50%, 60%, 80%, or 90% of the native, endogenous (i.e., non-isolated), full-length polypeptide of the present invention. Further, the proteins encoded by polynucleotides of this embodiment will optionally have a substantially similar affinity constant ( $K_m$ ) and/or catalytic activity (i.e., the microscopic rate constant,  $k_{cat}$ ) as the native endogenous, full-length protein. Those of skill in the art will recognize that  $k_{cat}/K_m$  value determines the specificity for competing substrates and is often referred to as the specificity constant. Proteins of this embodiment can have a  $k_{cat}/K_m$  value at least 10% of a non-isolated full-length polypeptide of the present invention as determined using the endogenous substrate of that polypeptide. Optionally, the  $k_{cat}/K_m$  value will be at least 20%, 30%, 40%, 50%, and most preferably at least 60%, 70%, 80%, 90%, or 95% the  $k_{cat}/K_m$  value of the non-isolated, full-length polypeptide of the present invention.

Determination of  $k_{cat}$ ,  $K_m$ , and  $k_{cat}/K_m$  can be determined by any number of means well known to those of skill in the art. For example, the initial rates (i.e., the first 5% or less of the reaction) can be determined using rapid mixing and sampling techniques (e.g., continuous-flow, stopped-flow, or rapid quenching techniques), flash photolysis, or relaxation methods (e.g., temperature jumps) in conjunction with such exemplary

- 30 -

methods of measuring as spectrophotometry, spectrofluorimetry, nuclear magnetic resonance, or radioactive procedures. Kinetic values are conveniently obtained using a Lineweaver-Burk or Eadie-Hofstee plot.

5 *F. Polynucleotides Complementary to the Polynucleotides of (A)-(E)*

As indicated in (f), *supra*, the present invention provides isolated nucleic acids comprising polynucleotides complementary to the polynucleotides of paragraphs A-E, above. As those of skill in the art will recognize, complementary sequences base-pair throughout the entirety of their length with the polynucleotides of (A)-(E) (i.e., have 10 100% sequence identity over their entire length). Complementary bases associate through hydrogen bonding in double stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

15 *G. Polynucleotides Which are Subsequences of the Polynucleotides of (A)-(F)*

As indicated in (g), *supra*, the present invention provides isolated nucleic acids comprising polynucleotides which comprise at least 15 contiguous bases from the polynucleotides of (A) through (F) as discussed above. The length of the polynucleotide is given as an integer selected from the group consisting of from at least 15 to the length 20 of the nucleic acid sequence from which the polynucleotide is a subsequence of. Thus, for example, polynucleotides of the present invention are inclusive of polynucleotides comprising at least 15, 20, 25, 30, 40, 50, 60, 75, or 100 contiguous nucleotides in length from the polynucleotides of (A)-(F). Optionally, the number of such subsequences encoded by a polynucleotide of the instant embodiment can be any integer 25 selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

The subsequences of the present invention can comprise structural characteristics of the sequence from which it is derived. Alternatively, the subsequences can lack 30 certain structural characteristics of the larger sequence from which it is derived. For example, a subsequence from a polynucleotide encoding a polypeptide having at least one linear epitope in common with a prototype polypeptide sequence as provided in (a), *supra*, may encode an epitope in common with the prototype sequence. Alternatively,

the subsequence may not encode an epitope in common with the prototype sequence but can be used to isolate the larger sequence by, for example, nucleic acid hybridization with the sequence from which it's derived. Subsequences can be used to modulate or detect gene expression by introducing into the subsequences compounds which bind,

5 intercalate, cleave and/or crosslink to nucleic acids. Exemplary compounds include acridine, psoralen, phenanthroline, naphthoquinone, daunomycin or chloroethylaminoaryl conjugates.

#### Construction of Nucleic Acids

10 The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, (b) synthetic techniques, or combinations thereof. In some embodiments, the polynucleotides of the present invention will be cloned, amplified, or otherwise constructed from a monocot. In preferred embodiments the monocot is *Zea mays*.

15 The nucleic acids may conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences may be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a

20 hexa-histidine marker sequence provides a convenient means to purify the proteins of the present invention. A polynucleotide of the present invention can be attached to a vector, adapter, or linker for cloning and/or expression of a polynucleotide of the present invention. Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell.

25 Typically, the length of a nucleic acid of the present invention less the length of its polynucleotide of the present invention is less than 20 kilobase pairs, often less than 15 kb, and frequently less than 10 kb. Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art. For a description of 30 various nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, IL).

#### *A. Recombinant Methods for Constructing Nucleic Acids*

The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from plant biological sources using any number of cloning methodologies known to those of skill in the art. In some 5 embodiments, oligonucleotide probes which selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. While isolation of RNA, and construction of cDNA and genomic libraries is well known to those of ordinary skill in the art, the following highlights some of the methods employed.

10

##### *A1. mRNA Isolation and Purification*

Total RNA from plant cells comprises such nucleic acids as mitochondrial RNA, chloroplastic RNA, rRNA, tRNA, hnRNA and mRNA. Total RNA preparation typically involves lysis of cells and removal of proteins, followed by precipitation of nucleic 15 acids. Extraction of total RNA from plant cells can be accomplished by a variety of means. Frequently, extraction buffers include a strong detergent such as SDS and an organic denaturant such as guanidinium isothiocyanate, guanidine hydrochloride or phenol. Following total RNA isolation, poly(A)<sup>+</sup> mRNA is typically purified from the remainder RNA using oligo(dT) cellulose. Exemplary total RNA and mRNA isolation 20 protocols are described in *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995). Total RNA and mRNA isolation kits are commercially available from vendors such as Stratagene (La Jolla, CA), Clonetech (Palo Alto, CA), Pharmacia (Piscataway, NJ), and 5'-3' (Paoli, 25 PA). See also, U.S. Patent Nos. 5,614,391; and, 5,459,253. The mRNA can be fractionated into populations with size ranges of about 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 kb. The cDNA synthesized for each of these fractions can be size selected to the same size range as its mRNA prior to vector insertion. This method helps eliminate truncated cDNA formed by incompletely reverse transcribed mRNA.

30

##### *A2. Construction of a cDNA Library*

Construction of a cDNA library generally entails five steps. First, first strand cDNA synthesis is initiated from a poly(A)<sup>+</sup> mRNA template using a poly(dT) primer or

random hexanucleotides. Second, the resultant RNA-DNA hybrid is converted into double stranded cDNA, typically by a combination of RNase H and DNA polymerase I (or Klenow fragment). Third, the termini of the double stranded cDNA are ligated to adaptors. Ligation of the adaptors will produce cohesive ends for cloning. Fourth, size selection of the double stranded cDNA eliminates excess adaptors and primer fragments, and eliminates partial cDNA molecules due to degradation of mRNAs or the failure of reverse transcriptase to synthesize complete first strands. Fifth, the cDNAs are ligated into cloning vectors and packaged. cDNA synthesis protocols are well known to the skilled artisan and are described in such standard references as: *Plant Molecular Biology*;

5 *A Laboratory Manual*; Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995). cDNA synthesis kits are available from a variety of commercial vendors such as Stratagene or Pharmacia.

10 A number of cDNA synthesis protocols have been described which provide substantially pure full-length cDNA libraries. Substantially pure full-length cDNA libraries are constructed to comprise at least 90%, and more preferably at least 93% or 95% full-length inserts amongst clones containing inserts. The length of insert in such libraries can be from 0 to 8, 9, 10, 11, 12, 13, or more kilobase pairs. Vectors to accommodate inserts of these sizes are known in the art and available commercially. See,

15 20 e.g., Stratagene's lambda ZAP Express (cDNA cloning vector with 0 to 12 kb cloning capacity).

An exemplary method of constructing a greater than 95% pure full-length cDNA library is described by Carninci *et al.*, *Genomics*, 37:327-336 (1996). In that protocol, the cap-structure of eukaryotic mRNA is chemically labeled with biotin. By using 25 streptavidin-coated magnetic beads, only the full-length first-strand cDNA/mRNA hybrids are selectively recovered after RNase I treatment. The method provides a high yield library with an unbiased representation of the starting mRNA population. Other methods for producing full-length libraries are known in the art. See, e.g., Edery *et al.*, *Mol. Cell Biol.*, 15(6):3363-3371 (1995); and, PCT Application WO 96/34981.

30

#### *A3. Normalized or Subtracted cDNA Libraries*

A non-normalized cDNA library represents the mRNA population of the tissue it was made from. Since unique clones are out-numbered by clones derived from highly

expressed genes their isolation can be laborious. Normalization of a cDNA library is the process of creating a library in which each clone is more equally represented.

A number of approaches to normalize cDNA libraries are known in the art. One approach is based on hybridization to genomic DNA. The frequency of each hybridized cDNA in the resulting normalized library would be proportional to that of each corresponding gene in the genomic DNA. Another approach is based on kinetics. If cDNA reannealing follows second-order kinetics, rarer species anneal less rapidly and the remaining single-stranded fraction of cDNA becomes progressively more normalized during the course of the hybridization. Specific loss of any species of cDNA, regardless of its abundance, does not occur at any Cot value. Construction of normalized libraries is described in Ko, *Nucl. Acids. Res.*, 18(19):5705-5711 (1990); Patanjali *et al.*, *Proc. Natl. Acad. U.S.A.*, 88:1943-1947 (1991); U.S. Patents 5,482,685, and 5,637,685. In an exemplary method described by Soares *et al.*, normalization resulted in reduction of the abundance of clones from a range of four orders of magnitude to a narrow range of only 1 order of magnitude. *Proc. Natl. Acad. Sci. USA*, 91:9228-9232 (1994).

Subtracted cDNA libraries are another means to increase the proportion of less abundant cDNA species. In this procedure, cDNA prepared from one pool of mRNA is depleted of sequences present in a second pool of mRNA by hybridization. The cDNA:mRNA hybrids are removed and the remaining un-hybridized cDNA pool is enriched for sequences unique to that pool. See, Foote *et al.* in, *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); Kho and Zarbl, *Technique*, 3(2):58-63 (1991); Sive and St. John, *Nucl. Acids Res.*, 16(22):10937 (1988); *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); and, Swaroop *et al.*, *Nucl. Acids Res.*, 19(8):1954 (1991). cDNA subtraction kits are commercially available. See, e.g., PCR-Select (Clontech).

#### *A4. Construction of a Genomic Library*

To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. Methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate molecular biological

techniques and instructions sufficient to direct persons of skill through many construction, cloning, and screening methodologies are found in Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Vols. 1-3 (1989), *Methods in Enzymology*, Vol. 152: *Guide to Molecular Cloning Techniques*, Berger and Kimmel, Eds., San Diego: Academic Press, Inc. (1987), *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997). Kits for construction of genomic libraries are also commercially available.

10

#### *A5. Nucleic Acid Screening and Isolation Methods*

The cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide of the present invention such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate 15 homologous genes in the same or different plant species. Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The 20 degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through manipulation of the concentration of formamide within the range of 0% to 50%. The degree of complementarity (sequence identity) required for detectable 25 binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will optimally be 100 percent; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and/or wash medium.

30

The nucleic acids of interest can also be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides of the present invention and related genes directly from genomic DNA or cDNA libraries. PCR and other *in vitro* amplification methods may also be useful, for example, to clone nucleic

-36-

acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, U.S. Patent No. 4,683,202 (1987); and, *PCR Protocols A Guide to Methods and Applications*, Innis *et al.*, Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

10 PCR-based screening methods have also been described. Wilfinger *et al.* describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. *BioTechniques*, 22(3): 481-486 (1997). In that method, a primer pair is synthesized with one primer annealing to the 5' end of the sense strand of the desired cDNA and the other primer to the vector. Clones are pooled to allow large-scale screening. By this procedure, the longest possible clone is identified amongst candidate clones. Further, the PCR product is used solely as a diagnostic for the presence of the desired cDNA and does not utilize the PCR product itself. Such methods are particularly effective in combination with a full-length cDNA construction methodology, *supra*.

20

#### *B. Synthetic Methods for Constructing Nucleic Acids*

The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang *et al.*, *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown *et al.*, *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage *et al.*, *Tetra. Lett.* 22: 1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, *Tetra. Letts.* 22(20): 1859-1862 (1981), e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter *et al.*, *Nucleic Acids Res.*, 12: 6159-6168 (1984); and, the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill will recognize that while chemical synthesis of

DNA is limited to sequences of about 100 bases, longer sequences may be obtained by the ligation of shorter sequences.

### Recombinant Expression Cassettes

5 The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention. A nucleic acid sequence coding for the desired polynucleotide of the present invention, for example a cDNA or a genomic sequence encoding a full length polypeptide of the present invention, can be used to construct a recombinant expression cassette which can be introduced into the desired host 10 cell. A recombinant expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences which will direct the transcription of the polynucleotide in the intended host cell, such as tissues of a transformed plant.

15 For example, plant expression vectors may include (1) a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a 20 transcription termination site, and/or a polyadenylation signal.

A plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of 25 constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin 1 promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No. 5,683,439), the *Nos* promoter, the pEmu promoter, the rubisco promoter, the GRP1-8 promoter, and other transcription initiation 30 regions from various plant genes known to those of skill. One exemplary promoter is the ubiquitin promoter, which can be used to drive expression of the present invention in embryos or embryogenic callus, particularly in maize.

Alternatively, the plant promoter can direct expression of a polynucleotide of the present invention in a specific tissue or may be otherwise under more precise environmental or developmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by 5 inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDK promoter which is inducible by light.

Examples of promoters under developmental control include promoters that 10 initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051). The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

15 Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue. Thus, in some 20 embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in *Zea mays*, operably linked to a polynucleotide of the present invention. Promoters useful in these embodiments include the endogenous promoters driving expression of a polypeptide of the present invention.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer 25 elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous promoters can be altered *in vivo* by mutation, deletion, and/or substitution (see, Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868), or isolated 30 promoters can be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene. Gene expression can be modulated under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition of the polypeptides of the present

invention in plant cell. Thus, the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous (i.e., non-heterologous) form of a polynucleotide of the present invention.

Methods for identifying promoters with a particular expression pattern, in terms of, e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. See, e.g., *The Maize Handbook*, Chapters 114-115, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3<sup>rd</sup> edition, Chapter 6, Sprague and Dudley, Eds., American Society of Agronomy, Madison, Wisconsin (1988). A typical step in promoter isolation methods is identification of gene products that are expressed with some degree of specificity in the target tissue. Amongst the range of methodologies are: differential hybridization to cDNA libraries; subtractive hybridization; differential display; differential 2-D protein gel electrophoresis; DNA probe arrays; and isolation of proteins known to be expressed with some specificity in the target tissue. Such methods are well known to those of skill in the art.

15. Commercially available products for identifying promoters are known in the art such as Clontech's (Palo Alto, CA) Universal GenomeWalker Kit.

For the protein-based methods, it is helpful to obtain the amino acid sequence for at least a portion of the identified protein, and then to use the protein sequence as the basis for preparing a nucleic acid that can be used as a probe to identify either genomic 20 DNA directly, or preferably, to identify a cDNA clone from a library prepared from the target tissue. Once such a cDNA clone has been identified, that sequence can be used to identify the sequence at the 5' end of the transcript of the indicated gene. For differential hybridization, subtractive hybridization and differential display, the nucleic acid sequence identified as enriched in the target tissue is used to identify the sequence at 25 the 5' end of the transcript of the indicated gene. Once such sequences are identified, starting either from protein sequences or nucleic acid sequences, any of these sequences identified as being from the gene transcript can be used to screen a genomic library prepared from the target organism. Methods for identifying and confirming the transcriptional start site are well known in the art.

30. In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each

- 40 -

particular gene in one or more other tissues of the plant. One can identify a promoter with activity in the desired tissue or condition but that do not have activity in any other common tissue.

To identify the promoter sequence, the 5' portions of the clones described here  
5 are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually an AT-rich stretch of 5-10 bp located approximately 20 to 40 base pairs upstream of the transcription start site. Identification of the TATA box is well known in the art. For example, one way to predict the location of this element is to identify the  
10 transcription start site using standard RNA-mapping techniques such as primer extension, S1 analysis, and/or RNase protection. To confirm the presence of the AT-rich sequence, a structure-function analysis can be performed involving mutagenesis of the putative region and quantification of the mutation's effect on expression of a linked downstream reporter gene. See, e.g., *The Maize Handbook*, Chapter 114, Freeling and Walbot,  
15 Eds., Springer, New York, (1994).

In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a ~~promoter element~~ (i.e., the CAAT box) with a series of adenines surrounding the trinucleotide G (or T) N G. J. Messing *et al.*, in *Genetic Engineering in Plants*, Kosage, Meredith and Hollaender, Eds., pp. 221-227 1983. In maize, there is no well  
20 conserved CAAT box but there are several short, conserved protein-binding motifs upstream of the TATA box. These include motifs for the trans-acting transcription factors involved in light regulation, anaerobic induction, hormonal regulation, or anthocyanin biosynthesis, as appropriate for each gene.

Once promoter and/or gene sequences are known, a region of suitable size is  
25 selected from the genomic DNA that is 5' to the transcriptional start, or the translational start site, and such sequences are then linked to a coding sequence. If the transcriptional start site is used as the point of fusion, any of a number of possible 5' untranslated regions can be used in between the transcriptional start site and the partial coding sequence. If the translational start site at the 3' end of the specific promoter is used,  
30 then it is linked directly to the methionine start codon of a coding sequence.

If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3'-end of a polynucleotide coding region. The polyadenylation region can be derived from the natural gene, from a variety of other

plant genes, or from T-DNA. The 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

An intron sequence can be added to the 5' untranslated region or the coding 5 sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. Buchman and Berg, *Mol. Cell Biol.* 8: 4395-4405 (1988); Callis *et al.*, *Genes Dev.* 1: 1183-1200 (1987).  
10 Such intron enhancement of gene expression is typically greatest when placed near the 5' end of the transcription unit. Use of maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. See generally, *The Maize Handbook*, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994).

The vector comprising the sequences from a polynucleotide of the present 15 invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g., the *aada* gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or 20 geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or *Hra* mutations), genes coding for resistance to 25 herbicides which act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the *bar* gene), or other such genes known in the art. The *bar* gene encodes resistance to the herbicide basta, the *nptII* gene encodes resistance to the antibiotics kanamycin and geneticin, and the ALS gene encodes resistance to the herbicide chlorsulfuron.

30 Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens* described by Rogers *et al.*, *Meth. in Enzymol.*, 153:253-277 (1987). These vectors are plant integrating vectors in that on transformation, the vectors

integrate a portion of vector DNA into the genome of the host plant. Exemplary *A. tumefaciens* vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl *et al.*, Gene, 61:1-11 (1987) and Berger *et al.*, Proc. Natl. Acad. Sci. U.S.A., 86:8402-8406 (1989). Another useful vector herein is plasmid pBI101.2 that is available from 5 Clontech Laboratories, Inc. (Palo Alto, CA).

A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics. Antisense technology can be conveniently used to gene expression in 10 plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, 15 e.g., Sheehy *et al.*, Proc. Nat'l. Acad. Sci. (USA) 85: 8805-8809 (1988); and Hiatt *et al.*, U.S. Patent No. 4,801,340.

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to 20 modulate expression of endogenous genes see, Napoli *et al.*, *The Plant Cell* 2: 279-289 (1990) and U.S. Patent No. 5,034,323.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby 25 functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described in Haseloff *et al.*, *Nature* 30 334: 585-591 (1988).

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov, V. V., *et al.*, *Nucleic Acids*

Res (1986) 14:4065-4076, describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. A report of similar work by the same group is that by Knorre, D. G., *et al.*, *Biochimie* (1985) 67:785-789. Iverson and Dervan also showed sequence-specific cleavage of single-stranded DNA mediated by incorporation of a modified nucleotide which was capable of activating cleavage (*J Am Chem Soc* (1987) 109:1241-1243). Meyer, R. B., *et al.*, *J Am Chem Soc* (1989) 111:8517-8519, effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides mediated by psoralen was disclosed by Lee, B. L., *et al.*, *Biochemistry* (1988) 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home, *et al.*, *J Am Chem Soc* (1990) 112:2435-2437. Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb and Matteucci, *J Am Chem Soc* (1986) 108:2764-2765; *Nucleic Acids Res* (1986) 14:7661-7674; Feteritz *et al.*, *J. Am. Chem. Soc.* 113:4000 (1991). Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and, 5,681941.

### Proteins

20 The isolated proteins of the present invention comprise a polypeptide having at least 10 amino acids encoded by any one of the polynucleotides of the present invention as discussed more fully, *supra*, or polypeptides which are conservatively modified variants thereof. The proteins of the present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length polypeptide of the present invention. Optionally, this subsequence of contiguous amino acids is at least 15, 20, 25, 30, 35, or 40 amino acids in length, often at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

30 The present invention further provides a protein comprising a polypeptide having a specified sequence identity with a polypeptide of the present invention. The percentage of sequence identity is an integer selected from the group consisting of from 50 to 99.

Exemplary sequence identity values include 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%. Sequence identity can be determined using, for example, the GAP or BLAST algorithms.

5 As those of skill will appreciate, the present invention includes catalytically active polypeptides of the present invention (i.e., enzymes). Catalytically active polypeptides have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity ( $k_{cat}/K_m$ ) is 10 optionally substantially similar to the native (non-synthetic), endogenous polypeptide. Typically, the  $K_m$  will be at least 30%, 40%, or 50%, that of the native (non-synthetic), endogenous polypeptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity ( $k_{cat}/K_m$ ), are well known to those of skill in the art.

15 Generally, the proteins of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention. Further, the proteins of the present invention will not bind to antisera raised against a polypeptide of the present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to 20 those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, *infra*. Thus, the proteins of the present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

25

#### Expression of Proteins in Host Cells

Using the nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacteria, yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and/or time), because they have been 30 genetically altered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the

present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the 5 DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To 10 obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications 15 may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification 20 sequences.

#### *A. Expression in Prokaryotes*

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains 25 may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., Nature 198:1056 (1977)), the tryptophan (trp) promoter system (Goeddel et al., Nucleic 30 Acids Res. 8:4057 (1980)) and the lambda derived P L promoter and N-gene ribosome binding site (Shimatake et al., Nature 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

- 46 -

The vector is selected to allow introduction into the appropriate host cell.

Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA.

5 Expression systems for expressing a protein of the present invention are available using *Bacillus* sp. and *Salmonella* (Palva, et al., *Gene* 22: 229-235 (1983); Mosbach, et al., *Nature* 302: 543-545 (1983)).

#### *B. Expression in Eukaryotes*

10 A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a of the present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells, as discussed *infra*, are employed as expression systems for production of the proteins of the instant invention.

15 Synthesis of heterologous proteins in yeast is well known. Sherman, F., et al., *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory (1982) is a well recognized work describing the various methods available to produce the protein in yeast. Two

widely utilized yeast for production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

20 A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.

25 The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been

- 47 -

developed in the art, and include the HEK293, BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV *tk* promoter or *pgk* (phosphoglycerate kinase) promoter), an enhancer (Queen *et al.*, *Immunol. Rev.* 89: 49 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, 1992).

10 Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See Schneider, *J. Embryol. Exp. Morphol.* 27: 353-365 (1987)).

15 As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, *et al.*, *J. Virol.* 45: 773-781 (1983)). Additionally, gene sequences to control replication 20 in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector in *DNA Cloning Vol. II a Practical Approach*, D.M. Glover, Ed., IRL Press, Arlington, Virginia pp. 213-238 (1985).

25 **Transfection/Transformation of Cells**

The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence 30 into the genome of a host cell to obtain the transcription and/or translation of the sequence to effect phenotypic changes in the organism. Thus, any method which provides for efficient transformation/transfection may be employed.

#### *A. Plant Transformation*

A DNA sequence coding for the desired polynucleotide of the present invention, for example a cDNA or a genomic sequence encoding a full length protein, will be used to construct a recombinant expression cassette which can be introduced into the desired plant.

Isolated nucleic acid acids of the present invention can be introduced into plants according techniques known in the art. Generally, recombinant expression cassettes as described above and suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in

the technical, scientific, and patent literature. See, for example, Weising *et al.*, *Ann. Rev. Genet.* 22: 421-477 (1988). For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment, silicon fiber delivery, or microinjection of plant cell protoplasts or embryogenic callus. See, e.g., Tomes, *et al.*, *Direct DNA Transfer* into Intact Plant Cells Via Microprojectile Bombardment. pp.197-213 in *Plant Cell, Tissue and Organ Culture, Fundamental Methods*. eds. O. L. Gamborg and G.C.

Phillips. Springer-Verlag Berlin Heidelberg New York, 1995. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. See, U.S. Patent No. 5,591,616.

The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski *et al.*, *Embo J.* 3: 2717-2722 (1984). Electroporation techniques are described in Fromm *et al.*, *Proc. Natl. Acad. Sci.* 82: 5824 (1985).

Ballistic transformation techniques are described in Klein *et al.*, *Nature* 327: 70-73 (1987). *Agrobacterium tumefaciens*-mediated transformation techniques are well described in the scientific literature. See, for example Horsch *et al.*, *Science* 233: 496-498 (1984), and Fraley *et al.*, *Proc. Natl. Acad. Sci.* 80: 4803 (1983). Although

*Agrobacterium* is useful primarily in dicots, certain monocots can be transformed by *Agrobacterium*. For instance, *Agrobacterium* transformation of maize is described in U.S. Patent No. 5,550,318.

Other methods of transfection or transformation include (1) *Agrobacterium rhizogenes*-mediated transformation (see, e.g., Lichtenstein and Fuller In: *Genetic Engineering*, vol. 6, PWJ Rigby, Ed., London, Academic Press, 1987; and Lichtenstein, C. P., and Draper, J., In: *DNA Cloning, Vol. II*, D. M. Glover, Ed., Oxford, IRI Press, 1985), Application PCT/US87/02512 (WO 88/02405 published Apr. 7, 1988) describes the use of *A.rhizogenes* strain A4 and its Ri plasmid along with *A. tumefaciens* vectors pARC8 or pARC16 (2) liposome-mediated DNA uptake (see, e.g., Freeman *et al.*, *Plant Cell Physiol.* 25: 1353, 1984), (3) the vortexing method (see, e.g., Kindle, *Proc. Natl. Acad. Sci., USA* 87: 1228, (1990)).

10 DNA can also be introduced into plants by direct DNA transfer into pollen as described by Zhou *et al.*, *Methods in Enzymology*, 101:433 (1983); D. Hess, *Intern Rev. Cytol.*, 107:367 (1987); Luo *et al.*, *Plane Mol. Biol. Reporter*, 6:165 (1988). Expression of polypeptide coding genes can be obtained by injection of the DNA into reproductive organs of a plant as described by Pena *et al.*, *Nature*, 325.:274 (1987).

15 DNA can also be injected directly into the cells of immature embryos and the rehydration of desiccated embryos as described by Neuhaus *et al.*, *Theor. Appl. Genet.*, 75:30 (1987); and Benbrook *et al.*, in *Proceedings Bio Expo 1986*, Butterworth, Stoneham, Mass., pp. 27-54 (1986). A variety of plant viruses that can be employed as vectors are known in the art and include cauliflower mosaic virus (CaMV), geminivirus, brome mosaic virus, and tobacco mosaic virus.

20

#### *B. Transfection of Prokaryotes, Lower Eukaryotes, and Animal Cells*

Animal and lower eukaryotic (e.g., yeast) host cells are competent or rendered competent for transfection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation, biolistics, and micro-injection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art. Kuchler, R.J., *Biochemical Methods in Cell Culture and Virology*, Dowden, Hutchinson and Ross, Inc. (1977).

### Synthesis of Proteins

The proteins of the present invention can be constructed using non-cellular synthetic methods. Solid phase synthesis of proteins of less than about 50 amino acids in length may be accomplished by attaching the C-terminal amino acid of the sequence to an insoluble support followed by sequential addition of the remaining amino acids in the sequence. Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis, pp. 3-284 in *The Peptides: Analysis, Synthesis, Biology*, Vol. 2: *Special Methods in Peptide Synthesis, Part A.*; Merrifield, et al., *J. Am. Chem. Soc.* 85: 2149-2156 (1963), and Stewart et al., *Solid Phase Peptide Synthesis*, 2nd ed., 5 Pierce Chem. Co., Rockford, Ill. (1984). Proteins of greater length may be synthesized by condensation of the amino and carboxy termini of shorter fragments. Methods of forming peptide bonds by activation of a carboxy terminal end (e.g., by the use of the coupling reagent N,N'-dicyclohexylcarbodiimide)) is known to those of skill.

10

15

### Purification of Proteins

The proteins of the present invention may be purified by standard techniques well known to those of skill in the art. Recombinantly-produced proteins of the present invention can be directly expressed or expressed as a fusion protein. The recombinant protein is purified by a combination of cell lysis (e.g., sonication, French press) and 20 affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme releases the desired recombinant protein.

The proteins of this invention, recombinant or synthetic, may be purified to substantial purity by standard techniques well known in the art, including detergent solubilization, selective precipitation with such substances as ammonium sulfate, column 25 chromatography, immunopurification methods, and others. See, for instance, R. Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag: New York (1982); Deutscher, *Guide to Protein Purification*, Academic Press (1990). For example, antibodies may be raised to the proteins as described herein. Purification from *E. coli* can be achieved following procedures described in U.S. Patent No. 4,511,503. The 30 protein may then be isolated from cells expressing the protein and further purified by standard protein chemistry techniques as described herein. Detection of the expressed protein is achieved by methods known in the art and include, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.

### Transgenic Plant Regeneration

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype. Such regeneration techniques often rely on manipulation of certain

5 phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with a polynucleotide of the present invention. For transformation and regeneration of maize see, Gordon-Kamm *et al.*, *The Plant Cell*, 2:603-618 (1990).

Plants cells transformed with a plant expression vector can be regenerated, e.g.,  
10 from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, Macmillan Publishing Company, New York, pp. 124-15 176 (1983); and Binding, *Regeneration of Plants, Plant Protoplasts*, CRC Press, Boca Raton, pp. 21-73 (1985).

The regeneration of plants containing the foreign gene introduced by *Agrobacterium* from leaf explants can be achieved as described by Horsch *et al.*, *Science*, 227:1229-1231 (1985). In this procedure, transformants are grown in the  
20 presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species being transformed as described by Fraley *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth.  
25 Transgenic plants of the present invention may be fertile or sterile.

Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.* 38: 467-486 (1987). The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, Methods for  
30 Plant Molecular Biology, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, Calif. (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots, rooting the transformant shoots and growth of the plantlets in soil. For maize cell culture and regeneration see generally, *The Maize*

*Handbook*, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3<sup>rd</sup> edition, Sprague and Dudley Eds., American Society of Agronomy, Madison, Wisconsin (1988).

One of skill will recognize that after the recombinant expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

In vegetatively propagated crops, mature transgenic plants can be propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants.

10 Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed propagated crops, mature transgenic plants can be self-crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants that would produce the selected phenotype.

15 Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid of the present invention. Progeny and variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.

20 Transgenic plants expressing the selectable marker can be screened for transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expression-positive plants. Standard

25 techniques for RNA analysis can be employed and include PCR amplification assays using oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition,

30 *in situ* hybridization and immunocytochemistry according to standard protocols can be done using heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Generally, a number

of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.

A preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid; i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered expression of a polynucleotide of the present invention relative to a control plant (i.e., native, non-transgenic). Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.

#### Modulating Polypeptide Levels and/or Composition

The present invention further provides a method for modulating (i.e., increasing or decreasing) the concentration or composition of the polypeptides of the present invention in a plant or part thereof. Modulation can be effected by increasing or decreasing the concentration and/or the composition (i.e., the ratio of the polypeptides of the present invention) in a plant. The method comprises transforming a plant cell with a recombinant expression cassette comprising a polynucleotide of the present invention as described above to obtain a transformed plant cell, growing the transformed plant cell under plant forming conditions, and inducing expression of a polynucleotide of the present invention in the plant for a time sufficient to modulate concentration and/or composition in the plant or plant part.

In some embodiments, the content and/or composition of polypeptides of the present invention in a plant may be modulated by altering, *in vivo* or *in vitro*, the promoter of a non-isolated gene of the present invention to up- or down-regulate gene expression. In some embodiments, the coding regions of native genes of the present invention can be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, e.g., Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868. And in some embodiments, an isolated nucleic acid (e.g., a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide of the present invention is selected for by means known to those of skill in the art such as, but not limited to,

Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or composition of 5 polypeptides of the present invention in the plant. Plant forming conditions are well known in the art and discussed briefly, *supra*.

In general, concentration or composition is increased or decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette. 10 Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide of the present invention in, for example, sense or antisense orientation as discussed in greater detail, *supra*. Induction of 15 expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds which activate expression from these promoters are well known in the art. In preferred embodiments, the polypeptides of the present invention are modulated in monocots, particularly maize.

20

### Molecular Markers

The present invention provides a method of genotyping a plant comprising a polynucleotide of the present invention. Preferably, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a 25 chromosome pair and can be used to differentiate segregants in a plant population.

Molecular marker methods can be used for phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance. See, e.g., *Plant Molecular Biology: A Laboratory Manual*,

30 Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, *The DNA Revolution* by Andrew H. Paterson 1996 (Chapter 2) in: *Genome Mapping in Plants* (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp.7-21.

The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic differences between DNA restriction fragments caused by nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single copy probes are preferred. Restriction fragments from homologous chromosomes are revealed. Differences in fragment size among alleles represent an RFLP. Thus, the present invention further provides a means to follow segregation of a gene or nucleic acid of the present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (cM), often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 3, 2, or 1 cM of a gene of the present invention.

In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize, under selective hybridization conditions, to a gene encoding a polynucleotide of the present invention. In preferred embodiments, the probes are selected from polynucleotides of the present invention. Typically, these probes are cDNA probes or *Pst I* genomic clones. The length of the probes is discussed in greater detail, *supra*, but are typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length. Preferably, the probes are single copy probes that hybridize to a unique locus in a haploid chromosome complement. Some exemplary restriction enzymes employed in RFLP mapping are EcoRI, EcoRV, and SstI. As used herein the term "restriction enzyme" includes reference to a composition that recognizes and, alone or in conjunction with another composition, cleaves at a specific nucleotide sequence.

The method of detecting an RFLP comprises the steps of (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present of said genomic DNA; (c) detecting therefrom a RFLP. Other methods of differentiating polymorphic (allelic) variants of polynucleotides of the present invention can be had by

utilizing molecular marker techniques well known to those of skill in the art including such techniques as: 1) single stranded conformation analysis (SSCA); 2) denaturing gradient gel electrophoresis (DGGE); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein; and 6) allele-specific PCR. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE); heteroduplex analysis (HA); and chemical mismatch cleavage (CMC). Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide of the present invention with a nucleic acid probe. Generally, the sample is a plant sample; preferably, a sample suspected of comprising a maize polynucleotide of the present invention (e.g., gene, mRNA). The nucleic acid probe selectively hybridizes, under stringent conditions, to a subsequence of a polynucleotide of the present invention comprising a polymorphic marker. Selective hybridization of the nucleic acid probe to the polymorphic marker nucleic acid sequence yields a hybridization complex. Detection of the hybridization complex indicates the presence of that polymorphic marker in the sample. In preferred embodiments, the nucleic acid probe comprises a polynucleotide of the present invention.

## 20 UTR's and Codon Preference

In general, translational efficiency has been found to be regulated by specific sequence elements in the 5' non-coding or untranslated region (5' UTR) of the RNA. Positive sequence motifs include translational initiation consensus sequences (Kozak, *Nucleic Acids Res.* 15:8125 (1987)) and the 7-methylguanosine cap structure (Drummond *et al.*, *Nucleic Acids Res.* 13:7375 (1985)). Negative elements include stable intramolecular 5' UTR stem-loop structures (Muesing *et al.*, *Cell* 48:691 (1987)) and AUG sequences or short open reading frames preceded by an appropriate AUG in the 5' UTR (Kozak, *supra*, Rao *et al.*, *Mol. and Cell. Biol.* 8:284 (1988)). Accordingly, the present invention provides 5' and/or 3' UTR regions for modulation of translation of heterologous coding sequences.

Further, the polypeptide-encoding segments of the polynucleotides of the present invention can be modified to alter codon usage. Altered codon usage can be employed to alter translational efficiency and/or to optimize the coding sequence for expression in a

desired host or to optimize the codon usage in a heterologous sequence for expression in maize. Codon usage in the coding regions of the polynucleotides of the present invention can be analyzed statistically using commercially available software packages such as "Codon Preference" available from the University of Wisconsin Genetics

5 Computer Group (see Devereaux *et al.*, *Nucleic Acids Res.* 12: 387-395 (1984)) or MacVector 4.1 (Eastman Kodak Co., New Haven, Conn.). Thus, the present invention provides a codon usage frequency characteristic of the coding region of at least one of the polynucleotides of the present invention. The number of polynucleotides that can be used to determine a codon usage frequency can be any integer from 1 to the number of 10 polynucleotides of the present invention as provided herein. Optionally, the polynucleotides will be full-length sequences. An exemplary number of sequences for statistical analysis can be at least 1, 5, 10, 20, 50, or 100.

#### Sequence Shuffling

15 The present invention provides methods for sequence shuffling using polynucleotides of the present invention, and compositions resulting therefrom. Sequence shuffling is described in PCT publication No. WO 97/20078. See also, Zhang, J.- H., *et al.* *Proc. Natl. Acad. Sci. USA* 94:4504-4509 (1997). Generally, sequence shuffling provides a means for generating libraries of polynucleotides having a desired 20 characteristic which can be selected or screened for. Libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides which comprise sequence regions which have substantial sequence identity and can be homologously recombined in vitro or in vivo. The population of sequence-recombined polynucleotides comprises a subpopulation of polynucleotides which possess desired or 25 advantageous characteristics and which can be selected by a suitable selection or screening method. The characteristics can be any property or attribute capable of being selected for or detected in a screening system, and may include properties of: an encoded protein, a transcriptional element, a sequence controlling transcription, RNA processing, RNA stability, chromatin conformation, translation, or other expression property of a 30 gene or transgene, a replicative element, a protein-binding element, or the like, such as any feature which confers a selectable or detectable property. In some embodiments, the selected characteristic will be a decreased  $K_m$  and/or increased  $K_{cat}$  over the wild-type protein as provided herein. In other embodiments, a protein or polynucleotide generated

from sequence shuffling will have a ligand binding affinity greater than the non-shuffled wild-type polynucleotide. The increase in such properties can be at least 110%, 120%, 130%, 140% or at least 150% of the wild-type value.

## 5 Generic and Consensus Sequences

Polynucleotides and polypeptides of the present invention further include those having: (a) a generic sequence of at least two homologous polynucleotides or polypeptides, respectively, of the present invention; and, (b) a consensus sequence of at least three homologous polynucleotides or polypeptides, respectively, of the present invention. The generic sequence of the present invention comprises each species of polypeptide or polynucleotide embraced by the generic polypeptide or polynucleotide, sequence, respectively. The individual species encompassed by a polynucleotide having an amino acid or nucleic acid consensus sequence can be used to generate antibodies or produce nucleic acid probes or primers to screen for homologs in other species, genera, families, orders, classes, phylums, or kingdoms. For example, a polynucleotide having a consensus sequences from a gene family of *Zea mays* can be used to generate antibody or nucleic acid probes or primers to other *Gramineae* species such as wheat, rice, or sorghum. Alternatively, a polynucleotide having a consensus sequence generated from orthologous genes can be used to identify or isolate orthologs of other taxa. Typically, a polynucleotide having a consensus sequence will be at least 9, 10, 15, 20, 25, 30, or 40 amino acids in length, or 20, 30, 40, 50, 100, or 150 nucleotides in length. As those of skill in the art are aware, a conservative amino acid substitution can be used for amino acids which differ amongst aligned sequence but are from the same conservative substitution group as discussed above. Optionally, no more than 1 or 2 conservative amino acids are substituted for each 10 amino acid length of consensus sequence.

Similar sequences used for generation of a consensus or generic sequence include any number and combination of allelic variants of the same gene, orthologous, or paralogous sequences as provided herein. Optionally, similar sequences used in generating a consensus or generic sequence are identified using the BLAST algorithm's smallest sum probability (P(N)). Various suppliers of sequence-analysis software are listed in chapter 7 of *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (Supplement 30). A polynucleotide sequence is considered similar to

a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, or 0.001, and most preferably less than about 0.0001, or 0.00001. Similar polynucleotides can be aligned and a consensus or generic sequence generated using

5 multiple sequence alignment software available from a number of commercial suppliers such as the Genetics Computer Group's (Madison, WI) PILEUP software, Vector NTI's (North Bethesda, MD) ALIGNX, or Genecode's (Ann Arbor, MI) SEQUENCER. Conveniently, default parameters of such software can be used to generate consensus or generic sequences.

10

#### Homology Searches

The present invention provides: 1) a machine having a memory comprising data representing a sequence of a polynucleotide or polypeptide of the present invention; 2) a data structure comprising a sequence of a polynucleotide of the present invention embodied in a computer readable media; and 3) a process for identifying a candidate homologue of a polynucleotide of the present invention. A candidate homologue has statistically significant probability of having the same function (e.g., catalyzes the same reaction) as the reference sequence to which it's compared. Unless otherwise provided for, software, electrical, and electronics terms as used herein are as defined in The New 20 IEEE Standard Dictionary of Electrical and Electronics Terms (5<sup>th</sup> edition, 1993).

The machine of the present invention is typically a digital computer. The memory of such a machine includes, but is not limited to, ROM, or RAM, or computer readable media such as, but not limited to, magnetic media such as computer disks or hard drives, or media such as CD-ROM. As those of skill in the art will be aware, the 25 form of memory of a machine of the present invention is not a critical element of the invention and can take a variety of forms.

The process of the present invention comprises obtaining data representing a polynucleotide or polypeptide test sequence. Test sequences are generally at least 25 amino acids in length or at least 50 nucleotides in length. Optionally, the test sequence 30 can be at least 50, 100, 150, 200, 250, 300, or 400 amino acids in length. A test polynucleotide can be at least 50, 100, 200, 300, 400, or 500 nucleotides in length. Often the test sequence will be a full-length sequence. Test sequences can be obtained from a nucleic acid of an animal or plant. Optionally, the test sequence is obtained from

- 60 -

a plant species other than maize whose function is uncertain but will be compared to the test sequence to determine sequence similarity or sequence identity; for example, such plant species can be of the family *Gramineae*, such as wheat, rice, or sorghum. The test sequence data is entered into a machine, typically a computer, having a memory which 5 contains data representing a reference sequence. The reference sequence can be the sequence of a polypeptide or a polynucleotide of the present invention and is often at least 25 amino acids or 100 nucleotides in length. As those of skill in the art are aware, the greater the sequence identity/similarity between a reference sequence of known 10 function and a test sequence, the greater the probability that the test sequence will have the same or similar function as the reference sequence.

The machine further comprises a sequence comparison means for determining the sequence identity or similarity between the test sequence and the reference sequence. Exemplary sequence comparison means are provided for in sequence analysis software discussed previously. Optionally, sequence comparison is established using the BLAST 15 suite of programs.

The results of the comparison between the test and reference sequences can be displayed. Generally, a smallest sum probability value (P(N)) of less than 0.1, or alternatively, less than 0.01, 0.001, 0.0001, or 0.00001 using the BLAST 2.0 suite of algorithms under default parameters identifies the test sequence as a candidate 20 homologue (i.e., an allele, ortholog, or paralog) of the reference sequence. A nucleic acid comprising a polynucleotide having the sequence of the candidate homologue can be constructed using well known library isolation, cloning, or *in vitro* synthetic chemistry techniques (e.g., phosphoramidite) such as those described herein. In additional 25 embodiments, a nucleic acid comprising a polynucleotide having a sequence represented by the candidate homologue is introduced into a plant; typically, these polynucleotides are operably linked to a promoter. Confirmation of the function of the candidate homologue can be established by operably linking the candidate homolog nucleic acid to, for example, an inducible promoter, or by expressing the antisense transcript, and analyzing the plant for changes in phenotype consistent with the presumed function of the 30 candidate homolog. Optionally, the plant into which these nucleic acids are introduced is a monocot such as from the family *Gramineae*. Exemplary plants include corn, sorghum, wheat, rice, canola, alfalfa, cotton, and soybean.

**Assays for Compounds that Modulate Enzymatic Activity or Expression**

The present invention also provides means for identifying compounds that bind to (e.g., substrates), and/or increase or decrease (i.e., modulate) the enzymatic activity of, catalytically active polypeptides of the present invention. The method comprises

- 5     contacting a polypeptide of the present invention with a compound whose ability to bind to or modulate enzyme activity is to be determined. The polypeptide employed will have at least 20%, preferably at least 30% or 40%, more preferably at least 50% or 60%, and most preferably at least 70% or 80% of the specific activity of the native, full-length polypeptide of the present invention (e.g., enzyme). Generally, the polypeptide will be
- 10    present in a range sufficient to determine the effect of the compound, typically about 1 nM to 10  $\mu$ M. Likewise, the compound will be present in a concentration of from about 1 nM to 10  $\mu$ M. Those of skill will understand that such factors as enzyme concentration, ligand concentrations (i.e., substrates, products, inhibitors, activators), pH, ionic strength, and temperature will be controlled so as to obtain useful kinetic data
- 15    and determine the presence of absence of a compound that binds or modulates polypeptide activity. Methods of measuring enzyme kinetics is well known in the art. See, e.g., Segel, *Biochemical Calculations*, 2<sup>nd</sup> ed., John Wiley and Sons, New York (1976).

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

**Example 1**

- 25    This example describes the construction of the cDNA libraries.

**Total RNA Isolation**

The RNA for SEQ ID NO: 1 was isolated from immature ear tissue from two ears of a B73 maize line. A B73 line seedling after a 10 day drought, heat shocked for 24 hours, and allowed to recover at normal growth conditions for 8 hrs, 16 hrs, and 24 hrs was the source for SEQ ID NO: 3. The polyA RNA used to prepare the library for SEQ ID NO: 5 was from W23 line tassels that were from 16-18cm long. All material used was cytologically staged and determined to contain meiocytes in the pachytene stage of

prophase I in the most mature portion of the tassel. The outer layer of endosperm (vitreous endosperm) of B73 maize line seed provided the RNA for SEQ ID NO: 7. Total RNA was isolated from corn tissues with TRIzol Reagent (Life Technology Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanate/acid-phenol procedure described by Chomczynski and Sacchi (Chomczynski, P., and Sacchi, N. *Anal. Biochem.* 162, 156 (1987)). In brief, plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. 10 The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.

#### Poly(A)+ RNA Isolation

The selection of poly(A)+ RNA from total RNA was performed using 15 PolyATtract system (Promega Corporation, Madison, WI). In brief, biotinylated oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed at high stringent condition and eluted by RNase-free deionized water.

20

#### cDNA Library Construction

cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the SuperScript Plasmid System (Life Technology Inc. Gaithersburg, MD). The first stand of cDNA was synthesized by priming an oligo(dT) primer 25 containing a Not I site. The reaction was catalyzed by SuperScript Reverse Transcriptase II at 45°C. The second strand of cDNA was labeled with alpha-<sup>32</sup>P-dCTP and a portion of the reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adapters were removed by Sephadex-S400 chromatography. The selected cDNA molecules were 30 ligated into pSPORT1 vector in between of Not I and Sal I sites.

#### Example 2

This example describes cDNA sequencing and library subtraction.

### Sequencing Template Preparation

Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid isolation. All the cDNA clones were sequenced using M13 reverse primers.

5

### Q-bot Subtraction Procedure

cDNA libraries subjected to the subtraction procedure were plated out on 22 x 22 cm<sup>2</sup> agar plate at density of about 3,000 colonies per plate. The plates were incubated in a 37°C incubator for 12-24 hours. Colonies were picked into 384-well plates by a robot colony picker, Q-bot (GENETIX Limited). These plates were incubated overnight at 37°C.

Once sufficient colonies were picked, they were pinned onto 22 x 22 cm<sup>2</sup> nylon membranes using Q-bot. Each membrane contained 9,216 colonies or 36,864 colonies. These membranes were placed onto agar plate with appropriate antibiotic. The plates were incubated at 37°C for overnight.

After colonies were recovered on the second day, these filters were placed on filter paper prewetted with denaturing solution for four minutes, then were incubated on top of a boiling water bath for additional four minutes. The filters were then placed on filter paper prewetted with neutralizing solution for four minutes. After excess solution was removed by placing the filters on dry filter papers for one minute, the colony side of the filters were placed into Proteinase K solution, incubated at 37°C for 40-50 minutes. The filters were placed on dry filter papers to dry overnight. DNA was then cross-linked to nylon membrane by UV light treatment.

Colony hybridization was conducted as described by Sambrook, J., Fritsch, E.F. and 25 Maniatis, T., (in Molecular Cloning: A laboratory Manual, 2<sup>nd</sup> Edition). The following probes were used in colony hybridization:

1. First strand cDNA from the same tissue as the library was made from to remove the most redundant clones.
2. 48-192 most redundant cDNA clones from the same library based on previous 30 sequencing data.
3. 192 most redundant cDNA clones in the entire corn sequence database.

4. A Sal-A20 oligo nucleotide: TCG ACC CAC GCG TCC GAA AAA AAA AAA AAA AAA AAA, listed in SEQ ID NO. 9, removes clones containing a poly A tail but no cDNA.
5. cDNA clones derived from rRNA.

5 The image of the autoradiography was scanned into computer and the signal intensity and cold colony addresses of each colony was analyzed. Re-arranging of cold-colonies from 384 well plates to 96 well plates was conducted using Q-bot.

### Example 3

10 This example describes identification of the gene from a computer homology search.

Gene identities were determined by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1990) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches under default parameters for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure

15 Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm. The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish, W. and States, D. J. (1993) *Nature Genetics* 3:266-272) provided by the NCBI. In some cases, the sequencing data from two or more clones containing overlapping segments of DNA were used to 20 construct contiguous DNA sequences.

### Example 4

This example describes the comparison of the maize and human Rad2/FEN-1 protein sequences.

- 65 -

Table 1

Comparison of Maize (SEQ ID NO. 4) and Human (SEQ ID NO. 10) Rad2/FEN-1 Protein Sequences

1	MGIKGLTKLADNAPKAMKEQKFESYFGRKIAVDASMSIYQFLIVVGRG 50
5	:         :     :     :     :     :     :     :     :
1	MGIQGLAKLIAADVAPSAIRENIDIKSYFGRKVAIDASMSIYQFLIAV. RQG 49
51	METLTNEAGEVTSHLQGMFNRTIRLLEAGIKPVYVFDGKPPDMKKQELAK 100
10	:         :     :     :     :     :     :     :     :
50	GDVLQNEEGETTSHLMGMFYRTIRMENGIKPVYVFDGKPPQLKSGELAK 99
101	RYS <u>KR</u> DDATKDLTEAVEVGDKDAIEKLSKRTVKVTRQHNEDCKRLLRLMG 150
100	:     :     :     :     :     :     :     :     :     :
15	RSERRAEAEKQLQQAQAAAGAEQEVEKFTKRLVKVTQHNDECKHLLSLMG 149
151	VPVVEAPSEAEAECAALCINDKVA <u>V</u> AVASE <u>D</u> MDSLT <u>F</u> GAPRFLRHLMDPSS 200
150	:     :     :     :     :     :     :     :     :     :
150	IPYLDAPSEAEASCAALVKAGKVYAAATE <u>D</u> MDCLTFGSPVLMRHLTASEA 199
20	KKIPVMEFDVAKVLEELTMDQFIDLCILCGCDYCDSIKGIGGQTALKL 250
200	:     :     :     :     :     :     :     :     :     :
200	KKLPIQEFHLSRILQELGLNQE <u>Q</u> FDLCILLGSDYCESIRGIGPKRAVDL 249
25	:     :     :     :     :     :     :     :     :     :
250	IRQHGSIESILENLNKDRYQI <u>P</u> EDWPYQE <u>AR</u> LFKEPNV. TLDIPELKWT 299
250	:     :     :     :     :     :     :     :     :     :
300	IQKHKSIEEIVRRLD <u>P</u> NKYPV <u>P</u> ENWLHKEAHQLFLEPEVLD <u>P</u> ESVELKWS 299
300	:     :     :     :     :     :     :     :     :     :
300	APDEEGLISFLVKDNGF <u>N</u> EDRVTKAIEKIKSAKNKSSQGRLESFFKPTAT 349
300	:     :     :     :     :     :     :     :     :     :
350	EPNEEELIKFMCGE <u>K</u> QFSEERIRSGVKRLSKSRQGSTQGRLLDDFFKVTGS 349
350	:     :     :     :     :     :     :     :     :     :
350	TSAPLKRKETSDKTSKAAANKKTKAGGKKK 379
350	:     :     :     :     :     :     :     :     :     :
350	LSS. AKRKEPEPKGSTKKAKTGAAGKFKR 378

35

Maize (SEQ ID NO. 4, shown on the top) and human (SEQ ID NO. 10, Accession Number P39748 or A56531, shown on the bottom) Rad2H sequences were compared using the Bestfit program of GCG. Percent Similarity: 64.191; Percent

Identity: 53.050. Consensus XPG signature motifs found in the Rad2/FEN1/XPG family of proteins are highlighted. Site directed mutagenesis of the human FEN-1 residues **D34, D86 or D181 (shown in bold)** to A did not affect substrate binding but resulted in loss of catalytic activity; mutagenesis of *E156, G231 or D233 (shown in Bold Italics)* to A residues caused loss of binding and catalysis, whereas mutation of R103 and D179 to A affected neither binding, nor catalysis.

### References

- 10 1. Prakash S. *et al.* (1993) *Ann. Rev. Genet.* 27, 33-70.
2. Habraken *et al.* (1993) *Nature* 366, 365-368
3. Harrington J and Lieber, M. (1994) *EMBO J.* 13, 1235-1246
4. Harrington J. and Lieber, M. (1994) *Genes Dev.* 8, 1344-1355
5. Alleva, J. *et al.* (1998) *Nucleic Acid Res.* 26, 3645-3650.
- 15 6. Kim K, *et al.* (1998) *J. Biol. Chem.* (1998) 273, 8842-8848.
7. Hiraoka *et al.* (1995) *Genomics* 25, 220-225
8. Shen *et al.* (1998) *TIBS* 23, 17-173
9. Kimura *et al.* (1997) *Nucleic Acid Reds.* 25, 4970-4976
10. Hosfield *et al.* (1998) *Cell* 95, 135-146.

20

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

**WHAT IS CLAIMED IS:**

1. An isolated nucleic acid comprising a member selected from the group consisting of:
  - (a) a polynucleotide having at least 60% sequence identity to a polynucleotide 5 encoding the polypeptide of SEQ ID NO: 2; wherein the percent sequence identity is determined according to the GAP program in the Wisconsin Genetics Software Package, using the default settings;
  - (b) a polynucleotide encoding the polypeptide of SEQ ID NO: 2;
  - (c) a polynucleotide amplified from a *Zea mays* nucleic acid library using primers 10 which selectively hybridize, under stringent hybridization conditions, to loci within the polynucleotide of SEQ ID NO: 1;
  - (d) a polynucleotide which selectively hybridizes, under stringent hybridization conditions and a wash in 2X SSC at 50°C, to the polynucleotide of SEQ ID NO: 1;
  - (e) the polynucleotide of SEQ ID NO: 1;
  - (f) a polynucleotide which is complementary to a polynucleotide of (a), (b), (c), (d), or (e); and
  - (g) a polynucleotide comprising at least 25 contiguous nucleotides from a 15 polynucleotide of (a), (b), (c), (d), (e), or (f).
2. A recombinant expression cassette, comprising a member of claim 1 operably linked; in sense or anti-sense orientation, to a promoter.
3. A host cell comprising the recombinant expression cassette of claim 2.
4. A transgenic plant comprising a recombinant expression cassette of claim 2.
5. The transgenic plant of claim 4, wherein said plant is a monocot.
6. The transgenic plant of claim 4, wherein said plant is a dicot.

7. The transgenic plant of claim 4, wherein said plant is selected from the group consisting of: maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, and millet.

5 8. A transgenic seed from the transgenic plant of claim 4.

9. A method of modulating the level of maize Rad2/FEN-1 in a plant, comprising:

10 (a) introducing into a plant cell a recombinant expression cassette comprising a maize Rad2/FEN-1 polynucleotide of claim 1 operably linked to a promoter;  
(b) culturing the plant cell under plant cell growing conditions; and  
(c) inducing expression of said polynucleotide for a time sufficient to modulate the level of maize Rad2/FEN-1 in said plant.

15 10. The method of claim 9, wherein the plant is maize.

11. An isolated protein comprising a member selected from the group consisting of:

20 (a) a polypeptide of at least 30 contiguous amino acids from the polypeptide of SEQ ID NO: 2;  
(b) the polypeptide of SEQ ID NO: 2;  
(c) a polypeptide having at least 80% sequence identity to, and having at least one linear epitope in common with, the polypeptide of SEQ ID NO: 2; wherein the percent sequence identity is determined according to the GAP program in the Wisconsin Genetics Software Package, using the default settings; and  
25 (d) at least one polypeptide encoded by a member of claim 1.

## SEQUENCE LISTING

&lt;110&gt; Pioneer Hi-Bred International, Inc.

<120> Maize Rad2/FEN-1 Orthologues and Uses.  
Thereof

&lt;130&gt; 0961-PCT

<150> 60/112,332  
<151> 1998-12-15

&lt;160&gt; 10

&lt;170&gt; FastSEQ for Windows Version 3.0

<210> 1  
<211> 1463  
<212> DNA  
<213> Zea mays<220>  
<221> CDS  
<222> (85) ... (1221)

&lt;400&gt; 1

cacgagaata gctcgccggcc	gcccgttctt	gcccactcc	ggctcagccg	ccgcccccca	60	
ccgcacacag	ccgcgcaga	cgag	atg ggc atc	aag ggt ttg acg	aaa ctg	111
			Met Gly Ile Lys	Gly Leu Thr	Lys Leu	
			1	5		

ctg gcg gac aat	gct	ccc aag	gct	atg aag	gag cag	aag ttc gag	agc	159
Leu Ala Asp Asn	Ala	Pro Lys	Ala Met	Lys Glu	Gln Lys	Phe Glu	Ser	
10	15	20	25					

tac ttc ggc cgc	aaa atc	gcc gtc	gac gcc	agc atg	agc ata	tac cag		207
Tyr Phe Gly Arg	Lys Ile	Ala Val	Asp Ala	Ser Met	Ser Ile	Tyr Gln		
30	35							

ttc ctg att gta gtt gga	agg aca	ggc atg	gaa act	ctc aca	aat gaa		255
Phe Leu Ile Val Val	Gly Arg	Thr Gly	Met Glu	Thr Leu	Thr Asn	Glu	
45	50						

gct ggt gaa gtc act agt	cat ttg	caa gga	atg ttc	aac cgg	aca ata		303
Ala Gly Val Thr Ser	His Leu	Gln Gly	Met Phe	Asn Arg	Thr Ile		
60	65						

aga tta ctg gaa gcg	gga atc aag	cca gtt	tat gtt	ttt gat	ggc aag		351
Arg Leu Leu Glu Ala	Gly Ile Lys	Pro Val	Tyr Val	Phe Asp	Gly Lys		
75	80						

cct cct gat atg aag	aaa caa gag	ctt gct	aaa aga	tac tca	aaa aga		399
Pro Pro Asp Met	Lys Lys	Gln Glu	Leu Ala	Lys Arg	Tyr Ser	Lys Arg	
90	95			100		105	

gat gat gca acc	aaa gat	ctg act	gag gca	gta gag	gta gga	gat aaa		447
Asp Asp Ala Thr	Lys Asp	Leu Thr	Glu Ala	Val Glu	Val Gly	Asp Lys		
110				115		120		

gat gcg att gaa aaa ttg agc aag agg act gta aag gtc aca agg caa 495  
 Asp Ala Ile Glu Lys Leu Ser Lys Arg Thr Val Lys Val Thr Arg Gln  
 125 130 135

cac aac gaa gat tgt aaa cgg cta tta aga ctt atg ggg gtt cct gtt 543  
 His Asn Glu Asp Cys Lys Arg Leu Leu Arg Leu Met Gly Val Pro Val  
 140 145 150

gta gag gca cct tct gaa gca gaa gca gaa tgt gca gcc ctt tgc ata 591  
 Val Glu Ala Pro Ser Glu Ala Glu Ala Glu Cys Ala Ala Leu Cys Ile  
 155 160 165

aac gat aag gtg ttc gct gtt gct tca gaa gat atg gac tcc ctt act 639  
 Asn Asp Lys Val Phe Ala Val Ala Ser Glu Asp Met Asp Ser Leu Thr  
 170 175 180 185

ttt ggg gct cca cgg ttc ctt cgt cat tta atg gat cca agt tcc aag 687  
 Phe Gly Ala Pro Arg Phe Leu Arg His Leu Met Asp Pro Ser Ser Lys  
 190 195 200

aaa ata cct gtg atg gaa ttt gat gtt gcc aag gtt ttg gag gag ctt 735  
 Lys Ile Pro Val Met Glu Phe Asp Val Ala Lys Val Leu Glu Glu Leu  
 205 210 215

gaa ctc acc atg gac cag ttc att gat ttg tgc atc ctg tgt gga tgt 783  
 Glu Leu Thr Met Asp Gln Phe Ile Asp Leu Cys Ile Leu Cys Gly Cys  
 220 225 230

gac tat tgt gat agc atc aaa ggt atc ggg ggg caa aca gct ctg aaa 831  
 Asp Tyr Cys Asp Ser Ile Lys Gly Ile Gly Gly Gln Thr Ala Leu Lys  
 235 240 245

ctt att cgt caa cat ggg tcc ata gaa agc atc ttg gag aat ctt aat 879  
 Leu Ile Arg Gln His Gly Ser Ile Glu Ser Ile Leu Glu Asn Leu Asn  
 250 255 260 265

aaa gac aga tat caa att cct gag gac tgg cct tac caa gaa gct cga 927  
 Lys Asp Arg Tyr Gln Ile Pro Glu Asp Trp Pro Tyr Gln Glu Ala Arg  
 270 275 280

cgc ttg ttc aag gag cct aat gtc aca ttg gat att cct gag cta aaa 975  
 Arg Leu Phe Lys Glu Pro Asn Val Thr Leu Asp Ile Pro Glu Leu Lys  
 285 290 295

tgg act gca cct gat gag gag ggt ctc ata agt ttc ctg gta aaa gat 1023  
 Trp Thr Ala Pro Asp Glu Glu Gly Leu Ile Ser Phe Leu Val Lys Asp  
 300 305 310

aat ggt ttc aac gaa gat cgg gtg aca aag gcc ata gag aag atc aaa 1071  
 Asn Gly Phe Asn Glu Asp Arg Val Thr Lys Ala Ile Glu Lys Ile Lys  
 315 320 325

tct gcc aag aat aaa tcg tcg caa gga aga ctc gag tcc ttt ttc aag 1119  
 Ser Ala Lys Asn Lys Ser Ser Gln Gly Arg Leu Glu Ser Phe Phe Lys  
 330 335 340 345

cca act gcc acc aca tca gca ccc cta aaa cgg aag gag act tcg gat 1167  
 Pro Thr Ala Thr Thr Ser Ala Pro Leu Lys Arg Lys Glu Thr Ser Asp  
 350 355 360

aaa aca agc aag gca gct gcg aac aag aaa aca aag gct ggt gga aag 1215  
 Lys Thr Ser Lys Ala Ala Ala Asn Lys Lys Thr Lys Ala Gly Gly Lys  
 365 370 375

aag aaa taatcttggta tgcttgatgt acaactacga ctacgaaagc agcggtggcg 1271  
 Lys Lys

tgatcacttc gcttagatta tttactccc tgtttaact cagagcttg gtaaaagttt 1331  
 gctcatgttt caagctgggg taagtttagtt gtgtttgaag agattggtgt accaagtaac 1391  
 aaaacttatac gctgtttttt acttcttgta ctttgaagta aaaaaaaaaa aaaaaaaaaa 1451  
 aaaaaaaaaa aa 1463

<210> 2

<211> 379

<212> PRT

<213> Zea mays

<400> 2

Met Gly Ile Lys Gly Leu Thr Lys Leu Leu Ala Asp Asn Ala Pro Lys  
 1 5 10 15  
 Ala Met Lys Glu Gln Lys Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala  
 20 25 30  
 Val Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu Ile Val Val Gly Arg  
 35 40 45  
 Thr Gly Met Glu Thr Leu Thr Asn Glu Ala Gly Glu Val Thr Ser His  
 50 55 60  
 Leu Gln Gly Met Phe Asn Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile  
 65 70 75 80  
 Lys Pro Val Tyr Val Phe Asp Gly Lys Pro Pro Asp Met Lys Lys Gln  
 85 90 95  
 Glu Leu Ala Lys Arg Tyr Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu  
 100 105 110  
 Thr Glu Ala Val Glu Val Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser  
 115 120 125  
 Lys Arg Thr Val Lys Val Thr Arg Gln His Asn Glu Asp Cys Lys Arg  
 130 135 140  
 Leu Leu Arg Leu Met Gly Val Pro Val Val Glu Ala Pro Ser Glu Ala  
 145 150 155 160  
 Glu Ala Glu Cys Ala Ala Leu Cys Ile Asn Asp Lys Val Phe Ala Val  
 165 170 175  
 Ala Ser Glu Asp Met Asp Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu  
 180 185 190  
 Arg His Leu Met Asp Pro Ser Ser Lys Lys Ile Pro Val Met Glu Phe  
 195 200 205  
 Asp Val Ala Lys Val Leu Glu Leu Glu Leu Thr Met Asp Gln Phe  
 210 215 220  
 Ile Asp Leu Cys Ile Leu Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys  
 225 230 235 240  
 Gly Ile Gly Gly Gln Thr Ala Leu Lys Leu Ile Arg Gln His Gly Ser  
 245 250 255  
 Ile Glu Ser Ile Leu Glu Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro  
 260 265 270  
 Glu Asp Trp Pro Tyr Gln Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn  
 275 280 285  
 Val Thr Leu Asp Ile Pro Glu Leu Lys Trp Thr Ala Pro Asp Glu Glu  
 290 295 300  
 Gly Leu Ile Ser Phe Leu Val Lys Asp Asn Gly Phe Asn Glu Asp Arg  
 305 310 315 320  
 Val Thr Lys Ala Ile Glu Lys Ile Lys Ser Ala Lys Asn Lys Ser Ser  
 325 330 335

Gln Gly Arg Leu Glu Ser Phe Phe Lys Pro Thr Ala Thr Thr Ser Ala  
 340 345 350  
 Pro Leu Lys Arg Lys Glu Thr Ser Asp Lys Thr Ser Lys Ala Ala Ala  
 355 360 365  
 Asn Lys Lys Thr Lys Ala Gly Gly Lys Lys Lys  
 370 375

<210> 3  
 <211> 1541  
 <212> DNA  
 <213> Zea mays

<220>  
 <221> CDS  
 <222> (79)...(1215)

<400> 3

gacccacgctg tccggcggtt tcttgcgcca ctccggctca gccgcccggcc gcccacccgccc 60  
 acagccgccc cagacgag atg ggc atc aag ggt ttg acg aaa ctg ctg gcg 111  
 Met Gly Ile Lys Gly Leu Thr Lys Leu Leu Ala  
 1 5 10

gac aat gcg ccc aag gcg atg aag gag cag aag ttc gag agc tac ttc 159  
 Asp Asn Ala Pro Lys Ala Met Lys Glu Gln Lys Phe Glu Ser Tyr Phe  
 15 20 25

ggc cgc aaa atc gcc gtc gac gcc agc atg agc ata tac cag ttc ctg 207  
 Gly Arg Lys Ile Ala Val Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu  
 30 35 40

att gta gtc gtc gga agg aca ggc atg gaa act ctc aca aat gaa gct ggt 255  
 Ile Val Val Gly Arg Thr Gly Met Glu Thr Leu Thr Asn Glu Ala Gly  
 45 50 55

gaa gtc act agt cat ttg caa gga atg ttc aac cgg aca ata aga tta 303  
 Glu Val Thr Ser His Leu Gln Gly Met Phe Asn Arg Thr Ile Arg Leu  
 60 65 70 75

ctg gaa gcg gga atc aag cca gtt tat gtt ttt gat ggc aag cct cct 351  
 Leu Glu Ala Gly Ile Lys Pro Val Tyr Val Phe Asp Gly Lys Pro Pro  
 80 85 90

gat atg aag aaa caa gag ctt gct aaa aga tac tca aaa aga gat gat 399  
 Asp Met Lys Lys Gln Glu Leu Ala Lys Arg Tyr Ser Lys Arg Asp Asp  
 95 100 105

gca acc aaa gat ctg act gag gca gta gag gta gga gat aaa gat gcg 447  
 Ala Thr Lys Asp Leu Thr Glu Ala Val Glu Val Gly Asp Lys Asp Ala  
 110 115 120

att gaa aaa ttg agc aag agg act gta aag gtc aca agg caa cac aac 495  
 Ile Glu Lys Leu Ser Lys Arg Thr Val Lys Val Thr Arg Gln His Asn  
 125 130 135

gaa gat tgt aaa cgg cta tta aga ctt atg ggg gtt cct gtt gta gag 543  
 Glu Asp Cys Lys Arg Leu Leu Arg Leu Met Gly Val Pro Val Val Glu  
 140 145 150 155

gca cct tct gaa gca gaa gca gaa tgt gca gcc ctt tgc ata aac gat 591  
 Ala Pro Ser Glu Ala Glu Ala Glu Cys Ala Ala Leu Cys Ile Asn Asp  
 160 165 170

aag gtg ttc gct gtt gct tca gaa gat atg gac tcc ctt act ttt ggg	639
Lys Val Phe Ala Val Ala Ser Glu Asp Met Asp Ser Leu Thr Phe Gly	
175 180 185	
gct cca cgg ttc ctt cgt cat tta atg gat cca agt tcc aag aaa ata	687
Ala Pro Arg Phe Leu Arg His Leu Met Asp Pro Ser Ser Lys Lys Ile	
190 195 200	
cct gtg atg gaa ttt gat gtt gcc aag gtt ttg gag gag ctt gaa ctc	735
Pro Val Met Glu Phe Asp Val Ala Lys Val Leu Glu Glu Leu Glu Leu	
205 210 215	
acc atg gac cag ttc att gat ttg tgc atc ctg tgg gga tgg gac tat	783
Thr Met Asp Gln Phe Ile Asp Leu Cys Ile Leu Cys Gly Cys Asp Tyr	
220 225 230 235	
tgg gat agc atc aaa ggt atc ggg ggg caa aca gct ctg aaa ctt att	831
Cys Asp Ser Ile Lys Gly Ile Gly Gln Thr Ala Leu Lys Leu Ile	
240 245 250	
cgt caa cat ggg tcc ata gaa agc atc ttg gag aat ctt aat aaa gac	879
Arg Gln His Gly Ser Ile Glu Ser Ile Leu Glu Asn Leu Asn Lys Asp	
255 260 265	
aga tat caa att cct gag gac tgg cct tac caa gaa gct cga cgc ttg	927
Arg Tyr Gln Ile Pro Glu Asp Trp Pro Tyr Gln Glu Ala Arg Arg Leu	
270 275 280	
ttc aag gag cct aat gtc aca ttg gat att cct gag cta aaa tgg act	975
Phe Lys Glu Pro Asn Val Thr Leu Asp Ile Pro Glu Leu Lys Trp Thr	
285 290 295	
gca cct gat gag gag ggt ctc ata agt ttc ctg gta aaa gat aat ggt	1023
Ala Pro Asp Glu Glu Gly Leu Ile Ser Phe Leu Val Lys Asp Asn Gly	
300 305 310 315	
ttc aac gaa gat cgg gtg aga aag gcc ata gag aag atc aaa tct gcc	1071
Phe Asn Glu Asp Arg Val Arg Lys Ala Ile Glu Lys Ile Lys Ser Ala	
320 325 330	
aag aat aaa tcg tcg caa gga aga ctc gag tcc ttt ttc aag cca act	1119
Lys Asn Lys Ser Ser Gln Gly Arg Leu Glu Ser Phe Phe Lys Pro Thr	
335 340 345	
gcc acc aca tca gca ccc cta aaa cgg aag gag act tcg gat aaa aca	1167
Ala Thr Thr Ser Ala Pro Leu Lys Arg Lys Glu Thr Ser Asp Lys Thr	
350 355 360	
agc aag gca gct gcg aac aag aaa aca aag gct ggt gga aag aag aaa	1215
Ser Lys Ala Ala Ala Asn Lys Lys Thr Lys Ala Gly Gly Lys Lys	
365 370 375	
taatcttggta gctttagtgt acaactacga ctacgaaagc agcggtggcg tgatcacttc	1275
gcttagatta tttaactccc ttttttaact cagagctttg gtaaaagttt gctcatgttt	1335
caagctgggg taagtttagt gtgtttgaag agattgtgtt accaagtaac aaaactatc	1395
gtgtttttt acttcttgc ctttgaagta tttatgccag tcctcgctt tttaagtatc	1455
tgtgttgcaaaaaattttta aggccttggtt ttgatgcata ggctcacttt aagatttagt	1515
ttaatttca aaaaaaaaaaaaaaaa	1541

&lt;210&gt; 4

&lt;211&gt; 379

&lt;212&gt; PRT

&lt;213&gt; Zea mays

&lt;400&gt; 4

Met Gly Ile Lys Gly Leu Thr Lys Leu Leu Ala Asp Asn Ala Pro Lys  
 1 5 10 15  
 Ala Met Lys Glu Gln Lys Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala  
 20 25 30  
 Val Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu Ile Val Val Gly Arg  
 35 40 45  
 Thr Gly Met Glu Thr Leu Thr Asn Glu Ala Gly Glu Val Thr Ser His  
 50 55 60  
 Leu Gln Gly Met Phe Asn Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile  
 65 70 75 80  
 Lys Pro Val Tyr Val Phe Asp Gly Lys Pro Pro Asp Met Lys Lys Gln  
 85 90 95  
 Glu Leu Ala Lys Arg Tyr Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu  
 100 105 110  
 Thr Glu Ala Val Glu Val Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser  
 115 120 125  
 Lys Arg Thr Val Lys Val Thr Arg Gln His Asn Glu Asp Cys Lys Arg  
 130 135 140  
 Leu Leu Arg Leu Met Gly Val Pro Val Val Glu Ala Pro Ser Glu Ala  
 145 150 155 160  
 Glu Ala Glu Cys Ala Ala Leu Cys Ile Asn Asp Lys Val Phe Ala Val  
 165 170 175  
 Ala Ser Glu Asp Met Asp Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu  
 180 185 190  
 Arg His Leu Met Asp Pro Ser Ser Lys Lys Ile Pro Val Met Glu Phe  
 195 200 205  
 Asp Val Ala Lys Val Leu Glu Glu Leu Glu Leu Thr Met Asp Gln Phe  
 210 215 220  
 Ile Asp Leu Cys Ile Leu Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys  
 225 230 235 240  
 Gly Ile Gly Gly Gln Thr Ala Leu Lys Leu Ile Arg Gln His Gly Ser  
 245 250 255  
 Ile Glu Ser Ile Leu Glu Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro  
 260 265 270  
 Glu Asp Trp Pro Tyr Gln Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn  
 275 280 285  
 Val Thr Leu Asp Ile Pro Glu Leu Lys Trp Thr Ala Pro Asp Glu Glu  
 290 295 300  
 Gly Leu Ile Ser Phe Leu Val Lys Asp Asn Gly Phe Asn Glu Asp Arg  
 305 310 315 320  
 Val Arg Lys Ala Ile Glu Lys Ile Lys Ser Ala Lys Asn Lys Ser Ser  
 325 330 335  
 Gln Gly Arg Leu Glu Ser Phe Phe Lys Pro Thr Ala Thr Thr Ser Ala  
 340 345 350  
 Pro Leu Lys Arg Lys Glu Thr Ser Asp Lys Thr Ser Lys Ala Ala Ala  
 355 360 365  
 Asn Lys Lys Thr Lys Ala Gly Gly Lys Lys Lys  
 370 375

&lt;210&gt; 5

&lt;211&gt; 1381

&lt;212&gt; DNA

&lt;213&gt; Zea mays

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (37) .. (1173)

&lt;400&gt; 5

cgacccacgc gtccggccac agccgcccga gacgag atg ggc atc aag ggt ttg 54  
 Met Gly Ile Lys Gly Leu  
 1 5

acg aaa ctg ctg gcg gac aat gcg ccc aag gcg atg aag gag cag aag 102  
 Thr Lys Leu Leu Ala Asp Asn Ala Pro Lys Ala Met Lys Glu Gln Lys  
 10 15 20

ttc gag agc tac ttc ggc cgc aaa atc gcc gtc gac gcc agc atg agc 150  
 Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala Val Asp Ala Ser Met Ser  
 25 30 35

ata tac cag ttc ctg att gta gtt gga agg aca ggc atg gaa act ctc 198  
 Ile Tyr Gln Phe Leu Ile Val Val Gly Arg Thr Gly Met Glu Thr Leu  
 40 45 50

aca aat gaa gct ggt gaa gtc act agt cat ttg caa gga atg ttc aac 246  
 Thr Asn Glu Ala Gly Glu Val Thr Ser His Leu Gln Gly Met Phe Asn  
 55 60 65 70

cgg aca ata aga tta ctg gaa gcg gga atc aag cca gtt tat gtt ttt 294  
 Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile Lys Pro Val Tyr Val Phe  
 75 80 85

gat ggc aag cct cct gat atg aag aaa caa gag ctt gct aaa aga tac 342  
 Asp Gly Lys Pro Pro Asp Met Lys Lys Gln Glu Leu Ala Lys Arg Tyr  
 90 95 100

tca aaa aga gat gat gca acc aaa gat ctg act gag gca gta gag gta 390  
 Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu Thr Glu Ala Val Glu Val  
 105 110 115

gga gat aaa gat gcg att gaa aaa ttg agc aag agg act gta aag gtc 438  
 Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser Lys Arg Thr Val Lys Val  
 120 125 130

aca agg caa cac aac gaa gat tgt aaa cgg cta tta aga ctt atg ggg 486  
 Thr Arg Gln His Asn Glu Asp Cys Lys Arg Leu Leu Arg Leu Met Gly  
 135 140 145 150

gtt cct gtt gta gag gca cct tct gaa gca gaa gca gaa tgt gca gcc 534  
 Val Pro Val Val Glu Ala Pro Ser Glu Ala Glu Ala Glu Cys Ala Ala  
 155 160 165

ctt tgc ata aac gat aag gtg ttc gct gtt gct tca gaa gat atg gac 582  
 Leu Cys Ile Asn Asp Lys Val Phe Ala Val Ala Ser Glu Asp Met Asp  
 170 175 180

tcc ctt act ttt ggg gct cca cgg ttc ctt cgt cat tta atg gat cca 630  
 Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu Arg His Leu Met Asp Pro  
 185 190 195

agt tcc aag aaa ata cct gtg atg gaa ttt gat gtt gcc aag gtt ttg 678  
 Ser Ser Lys Lys Ile Pro Val Met Glu Phe Asp Val Ala Lys Val Leu  
 200 205 210

gag gag ctt gaa ctc acc atg gac cag ttc att gat ttg tgc atc ctg 726  
 Glu Glu Leu Glu Leu Thr Met Asp Gln Phe Ile Asp Leu Cys Ile Leu  
 215 220 225 230

tgt gga tgt gac tat tgt gat agc atc aaa ggt atc ggg ggg caa aca 774  
 Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys Gly Ile Gly Gly Gln Thr  
 235 240 245

gct ctg aaa ctt att cgt caa cat ggg tcc ata gaa agc atc ttg gag 822  
 Ala Leu Lys Leu Ile Arg Gln His Gly Ser Ile Glu Ser Ile Leu Glu  
 250 255 260

aat ctt aat aaa gac aga tat caa att cct gag gac tgg cct tac caa 870  
 Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro Glu Asp Trp Pro Tyr Gln  
 265 270 275

gaa gct cga cgc ttg ttc aag gag cct aat gtc aca ttg gat att cct 918  
 Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn Val Thr Leu Asp Ile Pro  
 280 285 290

gag cta aaa tgg act gca cct gat gag gag ggt ctc ata agt ttc ctg 966  
 Glu Leu Lys Trp Thr Ala Pro Asp Glu Glu Gly Leu Ile Ser Phe Leu  
 295 300 305 310

gta aaa gat aat ggt ttc aac gaa gat cgg gtg aca aag gcc ata gag 1014  
 Val Lys Asp Asn Gly Phe Asn Glu Asp Arg Val Thr Lys Ala Ile Glu  
 315 320 325

aag atc aaa tct gcc aag aat aaa tcg tcg caa gga aga ctc gag tcc 1062  
 Lys Ile Lys Ser Ala Lys Asn Lys Ser Ser Gln Gly Arg Leu Glu Ser  
 330 335 340

ttt ttc aag cca act gcc acc aca tca gca ccg cta aaa cgg aag gag 1110  
 Phe Phe Lys Pro Thr Ala Thr Ser Ala Pro Leu Lys Arg Lys Glu  
 345 350 355

act tcg gat aaa aca agc aag gca gct gcg aac aag aaa aca aag gct 1158  
 Thr Ser Asp Lys Thr Ser Lys Ala Ala Asn Lys Lys Thr Lys Ala  
 360 365 370

ggt gga aag aag aaa taatcttggta tgcttgatgt acaactacga ctacgaaagc 1213  
 Gly Gly Lys Lys Lys  
 375

agcgggtggcg tgatcacttc gcttagatta tttaactccc tgttttact cagagcttg 1273  
 gtaaaaagtcc gcccatttt caagctgggg taagtttagtt gtgtttgaag agattgggt 1333  
 accaagtaac aaaacttatac gctgtttttt gaaaaaaaaaaaaaaa 1381

<210> 6  
 <211> 379  
 <212> PRT  
 <213> Zea mays

<400> 6

Met Gly Ile Lys Gly Leu Thr Lys Leu Leu Ala Asp Asn Ala Pro Lys  
 1 5 10 15  
 Ala Met Lys Glu Gln Lys Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala  
 20 25 30  
 Val Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu Ile Val Val Gly Arg  
 35 40 45  
 Thr Gly Met Glu Thr Leu Thr Asn Glu Ala Gly Glu Val Thr Ser His  
 50 55 60  
 Leu Gln Gly Met Phe Asn Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile  
 65 70 75 80

Lys Pro Val Tyr Val Phe Asp Gly Lys Pro Pro Asp Met Lys Lys Gln  
 85 90 95  
 Glu Leu Ala Lys Arg Tyr Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu  
 100 105 110  
 Thr Glu Ala Val Glu Val Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser  
 115 120 125  
 Lys Arg Thr Val Lys Val Thr Arg Gln His Asn Glu Asp Cys Lys Arg  
 130 135 140  
 Leu Leu Arg Leu Met Gly Val Pro Val Val Glu Ala Pro Ser Glu Ala  
 145 150 155 160  
 Glu Ala Glu Cys Ala Ala Leu Cys Ile Asn Asp Lys Val Phe Ala Val  
 165 170 175  
 Ala Ser Glu Asp Met Asp Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu  
 180 185 190  
 Arg His Leu Met Asp Pro Ser Ser Lys Lys Ile Pro Val Met Glu Phe  
 195 200 205  
 Asp Val Ala Lys Val Leu Glu Glu Leu Glu Leu Thr Met Asp Gln Phe  
 210 215 220  
 Ile Asp Leu Cys Ile Leu Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys  
 225 230 235 240  
 Gly Ile Gly Gly Gln Thr Ala Leu Lys Leu Ile Arg Gln His Gly Ser  
 245 250 255  
 Ile Glu Ser Ile Leu Glu Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro  
 260 265 270  
 Glu Asp Trp Pro Tyr Gln Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn  
 275 280 285  
 Val Thr Leu Asp Ile Pro Glu Leu Lys Trp Thr Ala Pro Asp Glu Glu  
 290 295 300  
 Gly Leu Ile Ser Phe Leu Val Lys Asp Asn Gly Phe Asn Glu Asp Arg  
 305 310 315 320  
 Val Thr Lys Ala Ile Glu Lys Ile Lys Ser Ala Lys Asn Lys Ser Ser  
 325 330 335  
 Gln Gly Arg Leu Glu Ser Phe Phe Lys Pro Thr Ala Thr Ser Ala  
 340 345 350  
 Pro Leu Lys Arg Lys Glu Thr Ser Asp Lys Thr Ser Lys Ala Ala Ala  
 355 360 365  
 Asn Lys Lys Thr Lys Ala Gly Gly Lys Lys Lys  
 370 375

<210> 7  
 <211> 1478  
 <212> DNA  
 <213> Zea mays

<220>  
 <221> CDS  
 <222> (97) ... (1233)

<400> 7

cgaccacgc gtcggggaaa tagctcgccgg tcgcggtttc ttgcgccact cccgctcagc 60  
 cggcccccgc caccggccac agccgcccga gacgag atg ggc atc aag ggt ttg 114  
 Met Gly Ile Lys Gly Leu  
 1 5

acg aaa ctg ctg gcg gac aat gcg ccc aag gcg atg aag gag cag aag 162  
 Thr Lys Leu Leu Ala Asp Asn Ala Pro Lys Ala Met Lys Glu Gln Lys  
 10 15 20

ttc gag agc tac ttc ggc cgc aaa atc gcc gtc gac gcc agc atg agc 210  
 Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala Val Asp Ala Ser Met Ser  
 25 30 35

atc tac cag ttc ctg ata gta gtt gga agg aca ggc atg gaa act ctc Ile Tyr Gln Phe Leu Ile Val Val Gly Arg Thr Gly Met Glu Thr Leu	258
40 45 50	
aca aat gaa gct ggt gaa gtc act agt cat ttg caa gga atg ttc aac Thr Asn Glu Ala Gly Glu Val Thr Ser His Leu Gln Gly Met Phe Asn	306
55 60 65 70	
cgg aca ata aga tta ctg gaa gcg gga atc aag cca gtt tat gtt ttt Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile Lys Pro Val Tyr Val Phe	354
75 80 85	
gat ggc aag cct cct gat atg aag aaa caa gaa ctt gct aaa aga tac Asp Gly Lys Pro Pro Asp Met Lys Lys Gln Glu Leu Ala Lys Arg Tyr	402
90 95 100	
tca aaa aga gat gat gca acc aaa gat ctg act gag gca gta gag gta- Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu Thr Glu Ala Val Glu Val	450
105 110 115	
gga gat aaa gat gcg att gaa aaa ttg agc aag agg act gta aag gtc Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser Lys Arg Thr Val Lys Val	498
120 125 130	
aca agg caa cac aac gaa gat tgt aaa cga cta tta aga ctt atg ggg Thr Arg Gln His Asn Glu Asp Cys Lys Arg Leu Leu Arg Leu Met Gly	546
135 140 145 150	
gtt cct gtt gta gag gca cct tct gaa gca gaa gca gaa tgt gca gcc Val Pro Val Val Glu Ala Pro Ser Glu Ala Glu Ala Glu Cys Ala Ala	594
155 160 165	
ctt tgc ata aac gat aag gtg ttc gct gtt gct tca gaa gat aag gac Leu Cys Ile Asn Asp Lys Val Phe Ala Val Ala Ser Glu Asp Lys Asp	642
170 175 180	
tcc ctt act ttt ggg gct cca cgg ttc ctt cgt cat tta atg gat cca Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu Arg His Leu Met Asp Pro	690
185 190 195	
agt tcc aag aaa ata cct gtg atg gaa ttt gat gtt gcc aag gtt ttg Ser Ser Lys Lys Ile Pro Val Met Glu Phe Asp Val Ala Lys Val Leu	738
200 205 210	
gag gag ctt gaa ctc acc atg gac cag ttc att gat ttg tgc atc ctg Glu Glu Leu Glu Leu Thr Met Asp Gln Phe Ile Asp Leu Cys Ile Leu	786
215 220 225 230	
tgt gga tgt gac tat tgt gat agc atc aaa ggt atc ggg ggg caa aca Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys Gly Ile Gly Gly Gln Thr	834
235 240 245	
gct ctg aaa ctt att cgt caa cat ggg tcc ata gaa agc atc ttg gag Ala Leu Lys Leu Ile Arg Gln His Gly Ser Ile Glu Ser Ile Leu Glu	882
250 255 260	
aat ctt aat aaa gac aga tat caa att cct gag gac tgg cct tac caa Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro Glu Asp Trp Pro Tyr Gln	930
265 270 275	

gaa gct cga cgc ttg ttc aag gag cct aat gtc act ttg gat att cct	978
Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn Val Thr Leu Asp Ile Pro	
280 285 290	
gag cta aaa tgg act gca cct gat gag gag ggt ctc ata agt ttc ctg	1026
Glu Leu Lys Trp Thr Ala Pro Asp Glu Gly Leu Ile Ser Phe Leu	
295 300 305 310	
gta aaa gat aat ggt ttc aat gaa gat cgg gtg aca aag gcc ata gag	1074
Val Lys Asp Asn Gly Phe Asn Glu Asp Arg Val Thr Lys Ala Ile Glu	
315 320 325	
aag atc aaa tct gcc aag aat aaa tcg tcg caa gga aga ctc gag tcc	1122
Lys Ile Lys Ser Ala Lys Asn Ser Ser Gln Gly Arg Leu Glu Ser	
330 335 340	
ttt ttc aag cca act gcc acc aca tca gca ccc cta aaa cgg aag gag	1170
Phe Phe Lys Pro Thr Ala Thr Ser Ala Pro Leu Lys Arg Lys Glu	
345 350 355	
act tcg gat aaa aca agc aag gca gct gcg aac aag aaa aca aag gct	1218
Thr Ser Asp Lys Thr Ser Lys Ala Ala Asn Lys Lys Thr Lys Ala	
360 365 370	
ggg gga aag aag aaa taatcttggta tgcttgatgt acaactacga ctacgaaagc	1273
Gly Gly Lys Lys Lys	
375	
agccgggtggca tgatcaacttc gcctagatta tttaactccc tggggtaact cagacccccc	1333
gtggaaagttt gcccattttt caagctgggg taagtttagtt gtggggaaag agattgggtgt	1393
accaagtaac aaaacttatac gctgtttttt acttcttgtc cttgaagta tggatgccag	1453
aaaaaaaaaaaa aaaaaaaaaaaa aaaaa	1478
<210> 8	
<211> 379	
<212> PRT	
<213> Zea mays	
<400> 8	
Met Gly Ile Lys Gly Leu Thr Lys Leu Ala Asp Asn Ala Pro Lys	
1 5 10 15	
Ala Met Lys Glu Gln Lys Phe Glu Ser Tyr Phe Gly Arg Lys Ile Ala	
20 25 30	
Val Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu Ile Val Val Gly Arg	
35 40 45	
Thr Gly Met Glu Thr Leu Thr Asn Glu Ala Gly Glu Val Thr Ser His	
50 55 60	
Leu Gln Gly Met Phe Asn Arg Thr Ile Arg Leu Leu Glu Ala Gly Ile	
65 70 75 80	
Lys Pro Val Tyr Val Phe Asp Gly Lys Pro Pro Asp Met Lys Lys Gln	
85 90 95	
Glu Leu Ala Lys Arg Tyr Ser Lys Arg Asp Asp Ala Thr Lys Asp Leu	
100 105 110	
Thr Glu Ala Val Glu Val Gly Asp Lys Asp Ala Ile Glu Lys Leu Ser	
115 120 125	
Lys Arg Thr Val Lys Val Thr Arg Gln His Asn Glu Asp Cys Lys Arg	
130 135 140	
Leu Leu Arg Leu Met Gly Val Pro Val Val Glu Ala Pro Ser Glu Ala	
145 150 155 160	
Glu Ala Glu Cys Ala Ala Leu Cys Ile Asn Asp Lys Val Phe Ala Val	
165 170 175	

Ala Ser Glu Asp Lys Asp Ser Leu Thr Phe Gly Ala Pro Arg Phe Leu  
 180 185 190  
 Arg His Leu Met Asp Pro Ser Ser Lys Lys Ile Pro Val Met Glu Phe  
 195 200 205  
 Asp Val Ala Lys Val Leu Glu Glu Leu Glu Leu Thr Met Asp Gln Phe  
 210 215 220  
 Ile Asp Leu Cys Ile Leu Cys Gly Cys Asp Tyr Cys Asp Ser Ile Lys  
 225 230 235 240  
 Gly Ile Gly Gly Gln Thr Ala Leu Lys Leu Ile Arg Gln His Gly Ser  
 245 250 255  
 Ile Glu Ser Ile Leu Glu Asn Leu Asn Lys Asp Arg Tyr Gln Ile Pro  
 260 265 270  
 Glu Asp Trp Pro Tyr Gln Glu Ala Arg Arg Leu Phe Lys Glu Pro Asn  
 275 280 285  
 Val Thr Leu Asp Ile Pro Glu Leu Lys Trp Thr Ala Pro Asp Glu Glu  
 290 295 300  
 Gly Leu Ile Ser Phe Leu Val Lys Asp Asn Gly Phe Asn Glu Asp Arg  
 305 310 315 320  
 Val Thr Lys Ala Ile Glu Lys Ile Lys Ser Ala Lys Asn Lys Ser Ser  
 325 330 335  
 Gln Gly Arg Leu Glu Ser Phe Phe Lys Pro Thr Ala Thr Thr Ser Ala  
 340 345 350  
 Pro Leu Lys Arg Lys Glu Thr Ser Asp Lys Thr Ser Lys Ala Ala Ala  
 355 360 365  
 Asn Lys Lys Thr Lys Ala Gly Gly Lys Lys Lys  
 370 375

&lt;210&gt; 9

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Designed oligonucleotide based upon an adaptor  
 used for cDNA library construction and poly(dT) to  
 remove clones which have a poly(A) tail but no  
 cDNA insert.

&lt;400&gt; 9

tcgaccacg cgtccggaaaa aaaaaaaaaaaa aaaaaaaaa

36

&lt;210&gt; 10

&lt;211&gt; 380

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

Met Gly Ile Gln Gly Leu Ala Lys Leu Ile Ala Asp Val Ala Pro Ser  
 1 5 10 15  
 Ala Ile Arg Glu Asn Asp Ile Lys Ser Tyr Phe Gly Arg Lys Val Ala  
 20 25 30  
 Ile Asp Ala Ser Met Ser Ile Tyr Gln Phe Leu Ile Ala Val Arg Gln  
 35 40 45  
 Gly Gly Asp Val Leu Gln Asn Glu Glu Gly Glu Thr Thr Ser His Leu  
 50 55 60  
 Met Gly Met Phe Tyr Arg Thr Ile Arg Met Met Glu Asn Gly Ile Lys  
 65 70 75 80  
 Pro Val Tyr Val Phe Asp Gly Lys Pro Pro Gln Leu Lys Ser Gly Glu  
 85 90 95

Leu Ala Lys Arg Ser Glu Arg Arg Ala Glu Ala Glu Lys Gln Leu Gln  
100 105 110  
Gln Ala Gln Ala Ala Gly Ala Glu Gln Glu Val Glu Lys Phe Thr Lys  
115 120 125  
Arg Leu Val Lys Val Thr Lys Gln His Asn Asp Glu Cys Lys His Leu  
130 135 140  
Leu Ser Leu Met Gly Ile Pro Tyr Leu Asp Ala Pro Ser Glu Ala Glu  
145 150 155 160  
Ala Ser Cys Ala Ala Leu Val Lys Ala Gly Lys Val Tyr Ala Ala Ala  
165 170 175  
Thr Glu Asp Met Asp Cys Leu Thr Phe Gly Ser Pro Val Leu Met Arg  
180 185 190  
His Leu Thr Ala Ser Glu Ala Lys Lys Leu Pro Ile Gln Glu Phe His  
195 200 205  
Leu Ser Arg Ile Leu Gln Glu Leu Gly Leu Asn Gln Glu Gln Phe Val  
210 215 220  
Asp Leu Cys Ile Leu Leu Gly Ser Asp Tyr Cys Glu Ser Ile Arg Gly  
225 230 235 240  
Ile Gly Pro Lys Arg Ala Val Asp Leu Ile Gln Lys His Lys Ser Ile  
245 250 255  
Glu Glu Ile Val Arg Arg Leu Asp Pro Asn Lys Tyr Pro Val Pro Glu  
260 265 270  
Asn Trp Leu His Lys Glu Ala His Gln Leu Phe Leu Glu Pro Glu Val  
275 280 285  
Leu Asp Pro Glu Ser Val Glu Leu Lys Trp Ser Glu Pro Asn Glu Glu  
290 295 300  
Glu Leu Ile Lys Phe Met Cys Gly Glu Lys Gln Phe Ser Glu Glu Arg  
305 310 315 320  
Ile Arg Ser Gly Val Lys Arg Leu Ser Lys Ser Arg Gln Gly Ser Thr  
325 330 335  
Gln Gly Arg Leu Asp Asp Phe Phe Lys Val Thr Gly Ser Leu Ser Ser  
340 345 350  
Ala Lys Arg Lys Glu Pro Glu Pro Lys Gly Ser Thr Lys Lys Lys Ala  
355 360 365  
Lys Thr Gly Ala Ala Gly Lys Phe Lys Arg Gly Lys  
370 375 380

# INTERNATIONAL SEARCH REPORT

Internet Application No  
PCT/US 99/27147

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>				
IPC 7	C12N15/29 A01H5/00	C12N15/55 A01H5/10	C12N1/19 C12N9/22	C12N1/21
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the International search (name of data base and, where practical, search terms used)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category *	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.
X	<p>DATABASE EMBL 'Online! Accession Number L26320, 26 May 1994 (1994-05-26) HARRINGTON JJ, LIEBER MR: "Mouse flap endonuclease-1 (FEN-1) mRNA" XP002137835 abstract</p>			1-3
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.				
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the International filing date but later than the priority date claimed				
"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the International search		Date of mailing of the International search report		
16 May 2000		29/05/2000		
Name and mailing address of the ISA		Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016		Bilang, J		

## INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/US 99/27147

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. 1-11
Y	KIMURA SEISUKE ET AL: "A structure-specific endonuclease from cauliflower ( <i>Brassica oleracea</i> var. <i>botrytis</i> ) inflorescence." NUCLEIC ACIDS RESEARCH DEC. 15, 1997, vol. 25, no. 24, 15 December 1997 (1997-12-15), pages 4970-4976, XP002137834 ISSN: 0305-1048 cited in the application the whole document	
Y	BINGHUI S ET AL: "Flap endonuclease homologs in archaeabacteria exist as independent proteins" TIBS TRENDS IN BIOCHEMICAL SCIENCES, EN, ELSEVIER PUBLICATION, CAMBRIDGE, vol. 23, no. 5, 1 May 1998 (1998-05-01), pages 171-173, XP004118516 ISSN: 0968-0004 the whole document	1-11
P, X	DATABASE EMBL 'Online! Accession Number AB021666, 29 December 1998 (1998-12-29) KIMURA S, ET AL.: "Oryza sativa OsFEN-1 mRNA" XP002137836 abstract	1-11
P, X	DATABASE EMBL 'Online! Accession Number AI881599, 23 July 1999 (1999-07-23) WALBOT V: "Maize ESTs from various cDNA libraries" XP002137837 abstract	1-11
T	KIMURA S, ET AL.: "Plant homologue of flap endonuclease-1: molecular cloning, characterization, and evidence of expression in meristematic tissues" PLANT MOLECULAR BIOLOGY, vol. 42, 2000, pages 415-427, XP000886911 the whole document	

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>C12N 15/29, 15/55, 1/19, 1/21, 5/10, A01H 5/00, 5/10, C12N 9/22</b></p>		<p>A1</p>	<p>(11) International Publication Number: <b>WO 00/36109</b></p> <p>(43) International Publication Date: <b>22 June 2000 (22.06.00)</b></p>
<p>(21) International Application Number: <b>PCT/US99/27147</b></p> <p>(22) International Filing Date: <b>16 November 1999 (16.11.99)</b></p> <p>(30) Priority Data: <b>60/112,332 15 December 1998 (15.12.98) US</b></p> <p>(71) Applicant (<i>for all designated States except US</i>): <b>PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 800 Capital Square, 400 Locust Street, Des Moines, IA 50309 (US).</b></p> <p>(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>): <b>MAHAJAN, Pramod, B. [US/US]; 8029 Brookview Drive, Urbandale, IA 50322 (US).</b></p> <p>(74) Agents: <b>YATES, Michael, E. et al.; Darwin Building, 7100 N.W. 62nd Avenue, Johnston, IA 50131-1000 (US).</b></p>		<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report.</i> <i>With amended claims.</i></p> <p><b>Date of publication of the amended claims:</b> <b>10 August 2000 (10.08.00)</b></p>	
<p>(54) Title: <b>MAIZE RAD2/FEN-1 ORTHOLOGUES AND USES THEREOF</b></p> <p>(57) Abstract</p> <p>The invention provides isolated maize Rad2/FEN-1 nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering maize Rad2/FEN-1 concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**AMENDED CLAIMS**

[received by the International Bureau on 13 June 2000 (13.06.00);  
original claim 1 amended; remaining claims unchanged (1 page)]

1. An isolated nucleic acid comprising a member selected from the group consisting of:
  - (a) a polynucleotide having at least 70% sequence identity to the polynucleotide of SEQ ID NO: 1; wherein the percent sequence identity is determined according to the GAP program in the Wisconsin Genetics Software Package, using the default settings;
  - (b) a polynucleotide encoding the polypeptide of SEQ ID NO: 2;
  - (c) a polynucleotide amplified from a *Zea mays* nucleic acid library using primers which selectively hybridize, under stringent hybridization conditions, to loci within the polynucleotide of SEQ ID NO: 1;
  - (d) a polynucleotide which selectively hybridizes, under stringent hybridization conditions and a wash in 1X SSC at 60°C, to the polynucleotide of SEQ ID NO: 1;
  - (e) the polynucleotide of SEQ ID NO: 1;
  - (f) a polynucleotide which is complementary to a polynucleotide of (a), (b), (c), (d), or (e); and
  - (g) a polynucleotide comprising at least 50 contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), (e), or (f).
20. 2. A recombinant expression cassette, comprising a member of claim 1 operably linked, in sense or anti-sense orientation, to a promoter.
3. A host cell comprising the recombinant expression cassette of claim 2.
- 25 4. A transgenic plant comprising a recombinant expression cassette of claim 2.
5. The transgenic plant of claim 4, wherein said plant is a monocot.
- 30 6. The transgenic plant of claim 4, wherein said plant is a dicot.

**THIS PAGE BLANK (USPTO)**